<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02222493</url>
  </required_header>
  <id_info>
    <org_study_id>B5371002</org_study_id>
    <secondary_id>REFLECTIONS B537-02</secondary_id>
    <secondary_id>2013-004148-49</secondary_id>
    <nct_id>NCT02222493</nct_id>
  </id_info>
  <brief_title>A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).</brief_title>
  <official_title>A Phase 3 Randomized, Double-blind Study Assessing The Efficacy And Safety Of Pf-06438179 And Infliximab In Combination With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the efficacy and safety of PF-06438179 and infliximab in combination&#xD;
      with methotrexate in subjects with active rheumatoid arthritis who have had an inadequate&#xD;
      response to methotrexate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 26, 2014</start_date>
  <completion_date type="Actual">June 1, 2017</completion_date>
  <primary_completion_date type="Actual">June 29, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1</measure>
    <time_frame>Week 14</time_frame>
    <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joint count (TJC); &gt;= 20% improvement in swollen joint count (SJC); and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity (PGA); physician global assessment of disease activity; self-assessed disability (health assessment questionnaire-disability index [HAQ-DI]); and C-Reactive Protein (CRP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2, 4, 6, 12, 22 and 30 (Pre-dose): Period 1</measure>
    <time_frame>Week 2, 4, 6, 12, 22 and 30 (pre-dose)</time_frame>
    <description>ACR20 response: &gt;=20% improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; HAQ-DI and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 38, 46 and 54 (Pre-dose): Period 2</measure>
    <time_frame>Week 38, 46 and 54 (pre-dose)</time_frame>
    <description>ACR20 response: &gt;=20% improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; HAQ-DI and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 62, 70 and 78: Period 3</measure>
    <time_frame>Week 62, 70 and 78</time_frame>
    <description>ACR20 response: &gt;=20% improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; HAQ-DI and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1</measure>
    <time_frame>Week 2, 4, 6, 12, 14, 22 and 30 (pre-dose)</time_frame>
    <description>ACR50 response: &gt;=50% improvement in tender joint count, &gt;=50% improvement in swollen joint count improvement and &gt;=50% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP. ACR70 response: &gt;=70% improvement in tender joint count, &gt;=70% improvement in swollen joint count improvement and &gt;=70% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2</measure>
    <time_frame>Week 38, 46 and 54 (pre-dose)</time_frame>
    <description>ACR50 response: &gt;=50% improvement in tender joint count, &gt;=50% improvement in swollen joint count improvement and &gt;=50% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP. ACR70 response: &gt;=70% improvement in tender joint count, &gt;=70% improvement in swollen joint count improvement and &gt;=70% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3</measure>
    <time_frame>Week 62, 70 and 78</time_frame>
    <description>ACR50 response: &gt;=50% improvement in tender joint count, &gt;=50% improvement in swollen joint count improvement and &gt;=50% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP. ACR70 response: &gt;=70% improvement in tender joint count, &gt;=70% improvement in swollen joint count improvement and &gt;=70% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1</measure>
    <time_frame>Baseline (Day 1), Week 2, 4, 6, 12, 14, 22 and 30</time_frame>
    <description>DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on visual analogue scale [VAS] from 0 to 100 mm; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) less than (&lt;)2.6=remission, &lt;3.2=low disease activity, &gt;=3.2-5.1=moderate disease activity and greater than (&gt;) 5.1=high disease activity. HAQ-DI assess degree of difficulty a participant experienced (past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2</measure>
    <time_frame>Baseline (Week 30 pre-dose), Week 38, 46 and 54</time_frame>
    <description>DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on VAS from 0 to 100 millimeter [mm]; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) &lt;2.6=remission, &lt;3.2=low disease activity, &gt;=3.2-5.1=moderate disease activity and &gt;5.1=high disease activity. HAQ-DI assess degree of difficulty a participant experienced (past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3</measure>
    <time_frame>Baseline (Week 54 pre-dose), Week 62, 70 and 78</time_frame>
    <description>DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on VAS from 0 to 100 mm; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) &lt;2.6=remission, &lt;3.2=low disease activity, &gt;=3.2-5.1=moderate disease activity and &gt;5.1=high disease activity. HAQ-DI assess degree of difficulty a participant experienced (past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS &lt;2.6) Remission: Period 1</measure>
    <time_frame>Week 2, 4, 6, 12, 14, 22 and Week 30 (pre-dose)</time_frame>
    <description>ACR/EULAR remission was considered if the scores on tender joint count, swollen joint count, hs-CRP (mg/dL), and patient's global assessment of arthritis (PGA) all were less than or equal to (=&lt;) 1 or the score on the simplified disease activity index (SDAI) was =&lt;3.3. SDAI was calculated as the sum of number of tender and swollen joint count (using 28 joints), PGA, physician global assessment, and CRP (mg/dL). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. Physician global assessment was recorded on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicated more disease activity. DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, CRP (mg/dL) and PGA using a 10 mm-VAS from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. DAS28 &lt;3.2: low disease activity, DAS28 &lt;2.6: remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS &lt;2.6) Remission: Period 2</measure>
    <time_frame>Week 38, 46 and 54 (pre-dose)</time_frame>
    <description>ACR/EULAR remission was considered if the scores on tender joint count, swollen joint count, hs-CRP (mg/dL), and PGA all were =&lt;1 or the score on the SDAI was =&lt;3.3. SDAI was calculated as the sum of number of tender and swollen joint count (using 28 joints), PGA, physician global assessment, and CRP (mg/dL). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. Physician global assessment was recorded on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicated more disease activity. DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, CRP (mg/dL) and PGA using a 10 mm-VAS from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. DAS28 &lt;3.2: low disease activity, DAS28 &lt;2.6: remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS &lt;2.6) Remission: Period 3</measure>
    <time_frame>Week 62, 70 and 78</time_frame>
    <description>ACR/EULAR remission was considered if the scores on tender joint count, swollen joint count, hs-CRP (mg/dL), and PGA all were =&lt;1 or the score on the SDAI was =&lt;3.3. SDAI was calculated as the sum of number of tender and swollen joint count (using 28 joints), PGA, physician global assessment, and CRP (mg/dL). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. Physician global assessment was recorded on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicated more disease activity. DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, CRP (mg/dL) and PGA using a 10 mm-VAS from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. DAS28 &lt;3.2: low disease activity, DAS28 &lt;2.6: remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1</measure>
    <time_frame>Week 2, 4, 6, 12, 14, 22 and Week 30 (pre-dose)</time_frame>
    <description>EULAR response was based on DAS28 EULAR response criteria which was defined as good response = DAS28 change of &gt;1.2 with DAS28 =&lt;3.2; moderate response = DAS28 change of &gt;0.6 to =&lt;1.2 with DAS28 &gt;3.2-5.1 and no-response = DAS28 change of =&lt;0.6 with DAS28 &gt;5.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2</measure>
    <time_frame>Week 38, 46 and Week 54 (pre-dose)</time_frame>
    <description>EULAR response was based on DAS28 EULAR response criteria which was defined as good response = DAS28 change of &gt;1.2 with DAS28 =&lt;3.2; moderate response = DAS28 change of &gt;0.6 to =&lt;1.2 with DAS28 &gt;3.2-5.1 and no-response = DAS28 change of =&lt;0.6 with DAS28 &gt;5.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3</measure>
    <time_frame>Week 62, 70 and Week 78</time_frame>
    <description>EULAR response was based on DAS28 EULAR response criteria which was defined as good response = DAS28 change of &gt;1.2 with DAS28 =&lt;3.2; moderate response = DAS28 change of &gt;0.6 to =&lt;1.2 with DAS28 &gt;3.2-5.1 and no-response = DAS28 change of =&lt;0.6 with DAS28 &gt;5.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 1</measure>
    <time_frame>Baseline (Day 1) up to Week 30</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Week 30 that were absent before treatment or that worsened relative to pre-treatment state. Treatment-related TEAE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non-serious adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 2</measure>
    <time_frame>Baseline (Week 30 pre-dose) up to Week 54</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Week 54 that were absent before treatment or that worsened relative to pre-treatment state. Treatment-related TEAE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non-serious adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 3</measure>
    <time_frame>Baseline (Week 54 pre-dose) up to Week 78</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Week 78 that were absent before treatment or that worsened relative to pre-treatment state. Treatment-related TEAE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non-serious adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs) of Grade 3 or Higher Severity: Period 1</measure>
    <time_frame>Baseline (Day 1) up to Week 30</time_frame>
    <description>AEs were graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) Version 4.03 as Grades 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life threatening AEs and Grade 5= death related to AE. AEs of Grade 3 and higher severity are reported in this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs) of Grade 3 or Higher Severity: Period 2</measure>
    <time_frame>Baseline (Week 30 pre-dose) up to Week 54</time_frame>
    <description>AEs were graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) Version 4.03 as Grades 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life threatening AEs and Grade 5= death related to AE. AEs of Grade 3 and higher severity are reported in this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs) of Grade 3 or Higher Severity: Period 3</measure>
    <time_frame>Baseline (Week 54 pre-dose) up to Week 78</time_frame>
    <description>AEs were graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) Version 4.03 as Grades 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life threatening AEs and Grade 5= death related to AE. AEs of Grade 3 and higher severity are reported in this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Abnormalities: Period 1</measure>
    <time_frame>Baseline (Day 1) up to Week 30</time_frame>
    <description>Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count, lymphocytes, neutrophils: &lt;0.8*lower limit of normal (LLN); platelets: &gt;1.75*upper limit of normal (ULN); white blood cell count: &lt;0.6*LLN; basophils, eosinophils, monocytes: &gt;1.2*ULN. liver function: bilirubin: &gt;1.5*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: &gt;3.0*ULN; protein, albumin: &lt;0.8*LLN&gt;&lt;/0&gt;1.2*ULN; renal function:blood urea nitrogen,creatinine: &gt;1.3*ULN; uric acid: &gt;1.2*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: &lt;0.9*LLN,&gt;1.1*ULN; urinalysis: pH&lt;4.5, &gt;8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: &lt;0.6*LLN,&gt;1.5*ULN). Participants with any laboratory abnormality in Period 1 were reported in this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Abnormalities: Period 2</measure>
    <time_frame>Baseline (Week 30 pre-dose) up to Week 54</time_frame>
    <description>Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count, lymphocytes, neutrophils: &lt;0.8*lower limit of normal (LLN); platelets: &gt;1.75*upper limit of normal (ULN); white blood cell count: &lt;0.6*LLN; basophils, eosinophils, monocytes: &gt;1.2*ULN. liver function: bilirubin: &gt;1.5*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: &gt;3.0*ULN; protein, albumin: &lt;0.8*LLN&gt;&lt;/0&gt;1.2*ULN; renal function:blood urea nitrogen,creatinine: &gt;1.3*ULN; uric acid: &gt;1.2*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: &lt;0.9*LLN,&gt;1.1*ULN; urinalysis: pH&lt;4.5, &gt;8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: &lt;0.6*LLN,&gt;1.5*ULN). Participants with any laboratory abnormality in Period 2 were reported in this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Abnormalities: Period 3</measure>
    <time_frame>Baseline (Week 54 pre-dose) up to Week 78</time_frame>
    <description>Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count, lymphocytes, neutrophils: &lt;0.8*lower limit of normal (LLN); platelets: &gt;1.75*upper limit of normal (ULN); white blood cell count: &lt;0.6*LLN; basophils, eosinophils, monocytes: &gt;1.2*ULN. liver function: bilirubin: &gt;1.5*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: &gt;3.0*ULN; protein, albumin: &lt;0.8*LLN&gt;&lt;/0&gt;1.2*ULN; renal function:blood urea nitrogen,creatinine: &gt;1.3*ULN; uric acid: &gt;1.2*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: &lt;0.9*LLN,&gt;1.1*ULN; urinalysis: pH&lt;4.5, &gt;8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: &lt;0.6*LLN,&gt;1.5*ULN). Participants with any laboratory abnormality in Period 3 were reported in this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1</measure>
    <time_frame>Baseline (Day 1), Week 2, 4, 6, 12, 14, 22 and Week 30</time_frame>
    <description>Tender joint count was an assessment of 68 joints (upper body, upper extremity, and lower extremity). Each joint's response to pressure/motion was assessed as: Present or Absent. Swollen joint count was an assessment of 66 joints (upper body, upper extremity, and lower extremity). Each joint was assessed for swelling as: Present or Absent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2</measure>
    <time_frame>Baseline (Week 30 pre-dose), Week 38, 46 and Week 54</time_frame>
    <description>Tender joint count was an assessment of 68 joints (upper body, upper extremity, and lower extremity). Each joint's response to pressure/motion was assessed as: Present or Absent. Swollen joint count was an assessment of 66 joints (upper body, upper extremity, and lower extremity). Each joint was assessed for swelling as: Present or Absent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3</measure>
    <time_frame>Baseline (Week 54 pre-dose), Week 62, 70 and 78</time_frame>
    <description>Tender joint count was an assessment of 68 joints (upper body, upper extremity, and lower extremity). Each joint's response to pressure/motion was assessed as: Present or Absent. Swollen joint count was an assessment of 66 joints (upper body, upper extremity, and lower extremity). Each joint was assessed for swelling as: Present or Absent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1</measure>
    <time_frame>Baseline (Day 1), Week 2, 4, 6, 12, 14, 22 and 30</time_frame>
    <description>PAAP: Participants assessed the severity of their arthritis pain by using a 100 mm VAS ranging from 0 (no pain) to 100 (most severe pain), which corresponded to the magnitude of their pain, where higher scores indicated more pain. PGA: Participants were asked the following question, &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; and their response was recorded on a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated worse health condition. PGAA: Participants were assessed how their overall arthritis appears at the time of the visit. The evaluation was based on the participant's disease signs, functional capacity and physical examination, and was independent of the PAAP and PGA assessments. The physician's response was recorded using a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated more disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2</measure>
    <time_frame>Baseline (Week 30 pre-dose), Week 38, 46 and 54</time_frame>
    <description>PAAP: Participants assessed the severity of their arthritis pain by using a 100 mm VAS ranging from 0 (no pain) to 100 (most severe pain), which corresponded to the magnitude of their pain, where higher scores indicated more pain. PGA: Participants were asked the following question, &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; and their response was recorded on a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated worse health condition. PGAA: Participants were assessed how their overall arthritis appears at the time of the visit. The evaluation was based on the participant's disease signs, functional capacity and physical examination, and was independent of the PAAP and PGA assessments. The physician's response was recorded using a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated more disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3</measure>
    <time_frame>Baseline (Week 54 pre-dose), Week 62, 70 and 78</time_frame>
    <description>PAAP: Participants assessed the severity of their arthritis pain by using a 100 mm VAS ranging from 0 (no pain) to 100 (most severe pain), which corresponded to the magnitude of their pain, where higher scores indicated more pain. PGA: Participants were asked the following question, &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; and their response was recorded on a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated worse health condition. PGAA: Participants were assessed how their overall arthritis appears at the time of the visit. The evaluation was based on the participant's disease signs, functional capacity and physical examination, and was independent of the PAAP and PGA assessments. The physician's response was recorded using a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated more disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1</measure>
    <time_frame>Baseline (Day 1), Week 2, 4, 6, 12, 14, 22 and 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 38, 46 and 54: Period 2</measure>
    <time_frame>Baseline (Week 30 pre-dose), Week 38, 46 and 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 62, 70 and 78: Period 3</measure>
    <time_frame>Baseline (Week 54 pre-dose), Week 62, 70 and 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (Nab) Status: Period 1</measure>
    <time_frame>Baseline (Day 1) up to Week 30</time_frame>
    <description>ADA positive results was defined as ADA titer level &gt;=1.30 and NAb positive was defined as NAb titer level &gt;=0.70.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (Nab) Status: Period 2</measure>
    <time_frame>Baseline (Week 30 pre-dose) up to Week 54</time_frame>
    <description>ADA positive results was defined as ADA titer level &gt;=1.30 and NAb positive was defined as NAb titer level &gt;=0.70.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (Nab) Status: Period 3</measure>
    <time_frame>Baseline (Week 54 pre-dose) up to Week 78</time_frame>
    <description>ADA positive results was defined as ADA titer level &gt;=1.30 and NAb positive was defined as NAb titer level &gt;=0.70.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration Versus Time Summary: Period 1</measure>
    <time_frame>Pre dose on Day 1, 15, 43, 99, 155 and 211; 2 hours post dose on Day 1 and 99; and 336 hours post dose on Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration Versus Time Summary: Period 2</measure>
    <time_frame>Pre dose on Day 211, 267, 379 and 547</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration Versus Time Summary: Period 3</measure>
    <time_frame>Pre dose on Day 379, 435 and 547</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">650</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>PF-06438179</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Infliximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06438179</intervention_name>
    <description>PF-06438179 will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.</description>
    <arm_group_label>PF-06438179</arm_group_label>
    <other_name>Infliximab-Pfizer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Infliximab will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.</description>
    <arm_group_label>Infliximab</arm_group_label>
    <other_name>Infliximab-EU, Remicade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Diagnosis of rheumatoid arthritis based on 2010 ACR/EULAR criteria for at least 4 months.&#xD;
&#xD;
        At least 6 tender (of 68 assessed) and 6 swollen (of 66 assessed) joints at screening and&#xD;
        baseline.&#xD;
&#xD;
        HS-CRP equal or greater than 10 mg/L.&#xD;
&#xD;
        Must have received methotrexate for at least 12 weeks and be on a stable dose for at least&#xD;
        4 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Evidence of untreated or inadequately treated latent or active TB.&#xD;
&#xD;
        Evidence or history of moderate or severe heart failure (NYHA Class III/IV)&#xD;
&#xD;
        Infection requiring hospitalization or parenteral antimicrobial therapy judged clinically&#xD;
        significant by the investigator within 6 months prior to first dose of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Achieve Clinical Research, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical and Translational Research Center of Alabama, PC</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Valley Arthritis Center, Ltd.</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Associates, P.C.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Osteoporosis Medical Center</name>
      <address>
        <city>La Palma</city>
        <state>California</state>
        <zip>90623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Rheumatology Clinical Trials, Inc.</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Valley Medical Group</name>
      <address>
        <city>Victorville</city>
        <state>California</state>
        <zip>92395</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Javed Rheumatology Associates, Inc</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Rheumatic Disease Specialties</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Medical Research</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Marcus Research Clinic, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advance Medical Research Services Corporation</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Arthritis Research Center</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alastair C. Kennedy, MD</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indian River Primary Care</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbin Clinic</name>
      <address>
        <city>Rome</city>
        <state>Georgia</state>
        <zip>30165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Medical Center of IL</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61636</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician's Clinic of Iowa, P.C.</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gilbert-Graves Clinic</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <zip>42101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Graves-Gilbert Clinic Bowling Green</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <zip>42101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Baton Rouge</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Diabetes Clinic, Inc.</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology and Bone Research</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Michigan University Homer Stryker MD School of Medicine Center for Clinical Research</name>
      <address>
        <city>Battle Creek</city>
        <state>Michigan</state>
        <zip>49015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis, Rheumatic &amp; Back Disease Associates</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Health Center-Medical Arts</name>
      <address>
        <city>Minot</city>
        <state>North Dakota</state>
        <zip>58701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Reading, LLC</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Low Country Rheumatology, PA</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Health Clinical Research</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Medical Clinic</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Tennessee Research Institute</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramesh C Gupta, MD</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Regional Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research</name>
      <address>
        <city>Nassau Bay</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacy Services, Sentara Leigh Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Medical Group, Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Seattle Arthritis Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast Private Hospital Pty Ltd</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HPS Pharmacies</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paradise Arthritis and Rheumatology Pty Ltd</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CliniPath Pathology</name>
      <address>
        <city>Osborne Park</city>
        <state>Western Australia</state>
        <zip>6017</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>R.K. Will Pty Ltd</name>
      <address>
        <city>Victoria Park</city>
        <state>Western Australia</state>
        <zip>6100</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center University of Sarajevo</name>
      <address>
        <city>Sarajevo</city>
        <state>Kanton Sarajevo</state>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital &quot;Prim.dr.Abdulah Nakas&quot;</name>
      <address>
        <city>Sarajevo</city>
        <state>Kanton Sarajevo</state>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Center Tuzla</name>
      <address>
        <city>Tuzla</city>
        <state>Tuzlanski Kanton</state>
        <zip>75000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Clinical Center Banja Luka</name>
      <address>
        <city>Banja Luka</city>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CETI - Centro de Estudos em Terapias Inovadoras</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80030-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Israelita Albert Einstein</name>
      <address>
        <city>São Paulo</city>
        <zip>05652-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Trimontium OOD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment (UMHAT) &quot;Kaspela&quot; EOOD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment (UMHAT) &quot;Sv. Ivan Rilski&quot; EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research and Arthritis Center</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 2C9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Czech Brno, s.r.o.</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lekarna Lancier, s.r.o.</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENU Lekarna</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR-SYNARC a.s.</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Czech Prague, s.r.o.</name>
      <address>
        <city>Praha 3</city>
        <zip>130 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lekarna U Robina, s.r.o.</name>
      <address>
        <city>Praha</city>
        <zip>130 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lekarna Hradebni s.r.o.</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDICAL PLUS, s.r.o.</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD Tbilisi Central Hospital</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD Unimedi Kakheti</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tbilisi Heart and Vascular Clinic LTD</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD MediClubGeorgia</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD Adapti</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD Medulla&quot; Chemotherapy and Immunotherapy Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schlosspark-Klinik</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth-Klinik gGmbH</name>
      <address>
        <city>Olsberg</city>
        <zip>59939</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaftsklinikum Saar GmbH</name>
      <address>
        <city>Puettlingen</city>
        <zip>66346</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ratingen</name>
      <address>
        <city>Ratingen</city>
        <zip>40878</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Médica Especializada en Medicina Interna y Reumatología</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Médica especializada en Medicina Interna</name>
      <address>
        <city>Guatemala</city>
        <zip>01011</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Nutricion y Rehabilitacion Cardiorespiratoria, S.A. (NUCARE)</name>
      <address>
        <city>Guatemala</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutic Research Institute and Lab S.A</name>
      <address>
        <city>Guatemala</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRC Gyógyszervizsgáló Központ Kft.</name>
      <address>
        <city>Balatonfüred</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qualiclinic Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Organization, Hadassah Medical Center, Ein-Karem</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anjo Kosei Hospital</name>
      <address>
        <city>Anjo-shi</city>
        <state>Aichi</state>
        <zip>446-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aso Iizuka Hospital</name>
      <address>
        <city>Iiduka</city>
        <state>Fukuoka</state>
        <zip>820-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inoue Hospital</name>
      <address>
        <city>Takasaki</city>
        <state>Gunma</state>
        <zip>370-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mazda Hospital</name>
      <address>
        <city>Aki-gun</city>
        <state>Hiroshima</state>
        <zip>735-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo City General Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8604</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsubara Mayflower Hospital</name>
      <address>
        <city>Katoh</city>
        <state>Hyogo</state>
        <zip>673-1462</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Sagamihara National Hospital</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0392</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Minami Kyosai Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>236-0037</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nagasaki Medical Center</name>
      <address>
        <city>Omura</city>
        <state>Nagasaki</state>
        <zip>856-8562</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sasebo Chuo Hospital</name>
      <address>
        <city>Sasebo</city>
        <state>Nagasaki</state>
        <zip>857-1195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurashiki Sweet Hospital</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <zip>710-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yuaikai Tomishiro Central Hospital</name>
      <address>
        <city>Tomigusuku</city>
        <state>Okinawa</state>
        <zip>901-0243</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical Center</name>
      <address>
        <city>Kawagoe-shi</city>
        <state>Saitama</state>
        <zip>350-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirose Clinic</name>
      <address>
        <city>Tokorozawa-shi</city>
        <state>Saitama</state>
        <zip>359-1111</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shizuoka Medical Center</name>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka</state>
        <zip>411-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's International Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Ohashi Medical Center</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <zip>153-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Showa University Hospital</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Chiba-East Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8712</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kondo clinic for rheumatism and orthopaedics</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Medical Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Orthopaedic Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>862-0976</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jordan Hospital</name>
      <address>
        <city>Amman</city>
        <zip>11152</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Abdullah University Hospital</name>
      <address>
        <city>Irbid</city>
        <zip>22110</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSMUL Kauno klinikos</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Alta Especialidad en Reumatología e Investigación del Potosí, S.C.</name>
      <address>
        <city>San Luis De Potosí</city>
        <state>SAN LUIS DE Potosi</state>
        <zip>78213</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigaciones Reumatológicas A.C - Hospital Central &quot;Dr. Ignacio Morones Prieto&quot;</name>
      <address>
        <city>Zona Universitaria</city>
        <state>SAN LUIS DE Potosi</state>
        <zip>CP 78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad Reumatologica Las Americas S.C.P</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <zip>CP 97000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Ayachi Hospital</name>
      <address>
        <city>Salé</city>
        <zip>11150</zip>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Radiologique de Salé</name>
      <address>
        <city>Salé</city>
        <zip>11150</zip>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laboratoire les Arcades d'Analyses Médicales</name>
      <address>
        <city>Salé</city>
        <zip>11150</zip>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital María Auxiliadora - Centro de Investigaciones Medicas</name>
      <address>
        <city>San juan de Miraflores</city>
        <state>Lima</state>
        <zip>Lima 29</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Ginecología y Reproducción &amp; Cirugía Mínimamente Invasiva</name>
      <address>
        <city>Santiago de Surco</city>
        <state>Lima</state>
        <zip>Lima 33</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de diagnóstico por imágenes, Radiología General y Especial</name>
      <address>
        <city>Arequipa</city>
        <zip>CP656</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigación en Medicina Interna y Enfermedades Críticas</name>
      <address>
        <city>Arequipa</city>
        <zip>CP656</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigación Reumatología CAA</name>
      <address>
        <city>Lima</city>
        <zip>Lima 27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Medica Cayetano Heredia</name>
      <address>
        <city>Lima</city>
        <zip>Lima 31</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Inmunología y Reumatología</name>
      <address>
        <city>Lima</city>
        <zip>Lima 31</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Mediatrix Medical Center</name>
      <address>
        <city>Lipa City</city>
        <state>Batangas</state>
        <zip>4217/043</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Philippines Medical Center</name>
      <address>
        <city>Davao</city>
        <state>Davao DEL SUR</state>
        <zip>8000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makati Medical Center</name>
      <address>
        <city>Makati</city>
        <state>Metro Manila</state>
        <zip>1229</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Manila</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philippine General Hospital</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Quezon</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki nr 2 im. dr. Jana Biziela w Bydgoszczy</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny im. J. Dietla Malopolskie Centrum Reumatologii Immunologii i Rehabilitacji</name>
      <address>
        <city>Krakow</city>
        <zip>31-121</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Lecznica MAK-MED. S.C.</name>
      <address>
        <city>Nadarzyn</city>
        <zip>05-830</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Twoja Przychodnia - Centrum Medyczne Nowa Sol</name>
      <address>
        <city>Nowa Sol</city>
        <zip>67-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MTZ Clinical Research Sp. z o.o.</name>
      <address>
        <city>Warszawa</city>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Galati &quot;Sf. Apostol Andrei&quot;</name>
      <address>
        <city>Galati</city>
        <zip>800578</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Recuperare Iasi</name>
      <address>
        <city>Iasi</city>
        <zip>700656</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Targu Mures</name>
      <address>
        <city>Targu Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBUZ &quot;Republican hospital n.a. V.A.Baranov&quot;</name>
      <address>
        <city>Petrozavodsk</city>
        <state>Republic OF Karelia</state>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GAUZ of Kemerovo Region &quot;Regional clinical hospital for war veterans&quot;</name>
      <address>
        <city>Kemerovo</city>
        <zip>650000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KGBUZ &quot;Krasnoyarsk Interdistrict Clinical Hospital #20 n.a. I.S.Berzon&quot;</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk State Medical University n.a.Prof.V.F.Voyno-Yasenetsky</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GMU &quot; Kursk regional clinical hospital&quot; of the Committee of Healthcare of the Kursk region</name>
      <address>
        <city>Kursk</city>
        <zip>305007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBUZ of city of Moscow</name>
      <address>
        <city>Moscow</city>
        <zip>129327</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBOU VPO &quot;Ryazan State medical university n.a. academician I.P.Pavlov&quot;</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBOUVPO &quot;Ryazan State Medical University n.a. Academician I.P.Pavlov&quot;</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBU of Ryazan region &quot;Regional clinical cardiology dispanser&quot;</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBOU of Ryazan region &quot;Regional clinical hospital&quot;</name>
      <address>
        <city>Ryazan</city>
        <zip>390039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spb GBUZ &quot;Clinical rheumatology hospital # 25&quot; City CDC prevention of osteoporosis</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>190068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GUZ &quot;Regional clinical hospital&quot;</name>
      <address>
        <city>Saratov</city>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBUZ VO 'Regional clinical hospital&quot;</name>
      <address>
        <city>Vladimir</city>
        <zip>600023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBKUZ of Yaroslavl region &quot;City hospital n. a. N.A. Semashko&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Bezanijska Kosa</name>
      <address>
        <city>Belgrade</city>
        <zip>11 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Belgrade</city>
        <zip>11 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Treatment and Rehabilitation &quot;Niska Banja&quot;</name>
      <address>
        <city>Niska Banja</city>
        <zip>18205</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Maxeke Johannesburg Academic Hospital</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jakaranda Hospital</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emmed Research</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0084</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinical Research Unit</name>
      <address>
        <city>Cape Town</city>
        <state>Western CAPE</state>
        <zip>7405</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vincent Pallotti Hospital</name>
      <address>
        <city>Cape Town</city>
        <state>Western CAPE</state>
        <zip>7405</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mohamed Kassab Institute of orthopedics</name>
      <address>
        <city>Manouba</city>
        <zip>2010</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabta Hospital</name>
      <address>
        <city>Tunis</city>
        <zip>1007</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derzhavna ustanova &quot;Ukrainskyi derzhavnyi naukovo-doslidnyi instytut</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oblasna klinichna likarnia, revmatolohichne viddilennia, Derzhavnyi vyshchyi navchalnyi zaklad</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Komunalnyi zaklad okhorony zdorovia &quot;Kharkivska miska klinichna likarnia #8&quot;</name>
      <address>
        <city>Kharkiv</city>
        <zip>61176</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khmelnytska oblasna likarnia</name>
      <address>
        <city>Khmelnytskyi</city>
        <zip>29000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyivska miska klinichna likarnia #6</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinichnyi hospital Derzhavnoi prykordonnoi sluzhby Ukrainy</name>
      <address>
        <city>Lviv</city>
        <zip>79014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Komunalnyi zaklad &quot;Kryvorizka miska klinichna likarnia #2&quot; Dnipropetrovskoi oblasnoi rady&quot;</name>
      <address>
        <city>M. Kryvyi Rih</city>
        <zip>50056</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Komunalnyi zaklad Sumskoi oblasnoi rady &quot;Sumska oblasna klinichna likarnia&quot;</name>
      <address>
        <city>M. Sumy</city>
        <zip>40022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytska oblasna klinichna likarnia im. M.I.Pyrohova, revmatolohichne</name>
      <address>
        <city>M. Vinnytsia</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Komunalna ustanova &quot;Odeska oblasna klinichna likarnia&quot;</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bahatoprofilnyi medychnyi tsentr (Universytetska klinika #1)</name>
      <address>
        <city>Odesa</city>
        <zip>65026</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Komunalna ustanova &quot;Zaporizka oblasna klinichna likarnia&quot; Zaporizkoi oblasnoi rady</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wrightington Hospital</name>
      <address>
        <city>Wigan</city>
        <state>Lancashire</state>
        <zip>WN6 9EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital, Maidstone and Tunbridge wells NHS Trust</name>
      <address>
        <city>Maidstone</city>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bosnia and Herzegovina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Jordan</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Morocco</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>Tunisia</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>France</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5371002&amp;StudyName=A%20Study%20of%20PF-06438179%20%28Infliximab-Pfizer%29%20and%20Infliximab%20in%20Combination%20with%20Methotrexate%20in%20Subjects%20with%20Active%20Rheumatoid%20Arthritis%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>August 19, 2014</study_first_submitted>
  <study_first_submitted_qc>August 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2014</study_first_posted>
  <results_first_submitted>June 26, 2017</results_first_submitted>
  <results_first_submitted_qc>August 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 11, 2017</results_first_posted>
  <disposition_first_submitted>June 26, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>June 26, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 27, 2017</disposition_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 3</keyword>
  <keyword>infliximab</keyword>
  <keyword>rheumatoid arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 1603 participants were screened after signing an informed consent form, of whom 650 participants were randomized to receive study treatment. One (1) participant in the PF-06438179 arm was screened and randomized by 2 different study site personnel, and no data were collected for the participant's second randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PF-06438179</title>
          <description>Participants received intravenous infusions of PF-06438179 at 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessments. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks. Participants initially randomized to PF-06438179 continued to blindly receive PF-06438179 in Period 2. A second randomization was blindly performed prior to dosing at Week 30 (at the beginning of Period 2, when participants initially randomized to INX were re-randomized in a 1:1 ratio, with 50% of the participants switching to PF-06438179 and the other 50% of participants remaining on the INX arm. Period 3 started with dosing at Week 54 where all participants began open label treatment with PF-06438179.</description>
        </group>
        <group group_id="P2">
          <title>Infliximab-EU Remicade (INX)</title>
          <description>Participants received intravenous infusions of INX at 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessments. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks. Participants initially randomized to PF-06438179 continued to blindly receive PF-06438179 in Period 2. A second randomization was blindly performed prior to dosing at Week 30 (at the beginning of Period 2), when participants initially randomized to INX were re-randomized in a 1:1 ratio, with 50% of the participants switching to PF-06438179 and the other 50% of participants remaining on the INX arm. Period 3 started with dosing at Week 54 where all participants began open label treatment with PF-06438179.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: First Dose-Week 30 (Pre-dose)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="324"/>
                <participants group_id="P2" count="326"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="323"/>
                <participants group_id="P2" count="326"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="280"/>
                <participants group_id="P2" count="286"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient clinical response</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2: Week30 Dosing-Week54(Pre-dose)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="423"/>
                <participants group_id="P2" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="380"/>
                <participants group_id="P2" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient clinical response</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3: Week 54 Dosing-Week 78 Visit</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="505"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="474"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Insufficient clinical response</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intent-to-Treat (ITT) Population was defined as all participants who were randomized to study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>PF-06438179</title>
          <description>Participants received intravenous infusions of PF-06438179 at 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessments. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks. Participants initially randomized to PF-06438179 continued to blindly receive PF-06438179 in Period 2. A second randomization was blindly performed prior to dosing at Week 30 (at the beginning of Period 2, when participants initially randomized to INX were re-randomized in a 1:1 ratio, with 50% of the participants switching to PF-06438179 and the other 50% of participants remaining on the INX arm. Period 3 started with dosing at Week 54 where all participants began open label treatment with PF-06438179.</description>
        </group>
        <group group_id="B2">
          <title>Infliximab-EU Remicade (INX)</title>
          <description>Participants received intravenous infusions of INX at 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessments. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks. Participants initially randomized to PF-06438179 continued to blindly receive PF-06438179 in Period 2. A second randomization was blindly performed prior to dosing at Week 30 (at the beginning of Period 2), when participants initially randomized to INX were re-randomized in a 1:1 ratio, with 50% of the participants switching to PF-06438179 and the other 50% of participants remaining on the INX arm. Period 3 started with dosing at Week 54 where all participants began open label treatment with PF-06438179.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="324"/>
            <count group_id="B2" value="326"/>
            <count group_id="B3" value="650"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.8" spread="13.3"/>
                    <measurement group_id="B2" value="52.8" spread="12.9"/>
                    <measurement group_id="B3" value="52.8" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="258"/>
                    <measurement group_id="B2" value="264"/>
                    <measurement group_id="B3" value="522"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1</title>
        <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joint count (TJC); &gt;= 20% improvement in swollen joint count (SJC); and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity (PGA); physician global assessment of disease activity; self-assessed disability (health assessment questionnaire-disability index [HAQ-DI]); and C-Reactive Protein (CRP).</description>
        <time_frame>Week 14</time_frame>
        <population>The ITT Population was defined as all participants who were randomized to study treatment. The primary analyses for ACR20 at Week 14 were performed with the missing data imputed using a non-responder imputation method.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 1: PF-06438179</title>
            <description>Participants were scheduled to receive intravenous infusions of PF-06438179 at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Period 1: Infliximab-EU Remicade (INX)</title>
            <description>Participants were scheduled to receive intravenous infusions of INX at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1</title>
          <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joint count (TJC); &gt;= 20% improvement in swollen joint count (SJC); and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity (PGA); physician global assessment of disease activity; self-assessed disability (health assessment questionnaire-disability index [HAQ-DI]); and C-Reactive Protein (CRP).</description>
          <population>The ITT Population was defined as all participants who were randomized to study treatment. The primary analyses for ACR20 at Week 14 were performed with the missing data imputed using a non-responder imputation method.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Score statistic method</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence test</non_inferiority_desc>
            <param_type>Proportion Difference</param_type>
            <param_value>-2.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.92</ci_lower_limit>
            <ci_upper_limit>5.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Score statistic method</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence test</non_inferiority_desc>
            <param_type>Proportion Difference</param_type>
            <param_value>-2.39</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.75</ci_lower_limit>
            <ci_upper_limit>4.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2, 4, 6, 12, 22 and 30 (Pre-dose): Period 1</title>
        <description>ACR20 response: &gt;=20% improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; HAQ-DI and CRP.</description>
        <time_frame>Week 2, 4, 6, 12, 22 and 30 (pre-dose)</time_frame>
        <population>The ITT Population was defined as all participants who were randomized to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 1: PF-06438179</title>
            <description>Participants were scheduled to receive intravenous infusions of PF-06438179 at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Period 1: Infliximab-EU Remicade (INX)</title>
            <description>Participants were scheduled to receive intravenous infusions of INX at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2, 4, 6, 12, 22 and 30 (Pre-dose): Period 1</title>
          <description>ACR20 response: &gt;=20% improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; HAQ-DI and CRP.</description>
          <population>The ITT Population was defined as all participants who were randomized to study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187"/>
                    <measurement group_id="O2" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210"/>
                    <measurement group_id="O2" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197"/>
                    <measurement group_id="O2" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 38, 46 and 54 (Pre-dose): Period 2</title>
        <description>ACR20 response: &gt;=20% improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; HAQ-DI and CRP.</description>
        <time_frame>Week 38, 46 and 54 (pre-dose)</time_frame>
        <population>The ITT Population was defined as all participants who were randomized to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2: PF-06438179/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of PF-06438179 in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O2">
            <title>Period 2: INX/INX</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive INX in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O3">
            <title>Period 2: INX/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 38, 46 and 54 (Pre-dose): Period 2</title>
          <description>ACR20 response: &gt;=20% improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; HAQ-DI and CRP.</description>
          <population>The ITT Population was defined as all participants who were randomized to study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54 (pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 62, 70 and 78: Period 3</title>
        <description>ACR20 response: &gt;=20% improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; HAQ-DI and CRP.</description>
        <time_frame>Week 62, 70 and 78</time_frame>
        <population>The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 3: PF-06438179/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of PF-06438179 in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O2">
            <title>Period 3: INX/INX/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O3">
            <title>Period 3: INX/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and PF-06438179 in Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 62, 70 and 78: Period 3</title>
          <description>ACR20 response: &gt;=20% improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; HAQ-DI and CRP.</description>
          <population>The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1</title>
        <description>ACR50 response: &gt;=50% improvement in tender joint count, &gt;=50% improvement in swollen joint count improvement and &gt;=50% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP. ACR70 response: &gt;=70% improvement in tender joint count, &gt;=70% improvement in swollen joint count improvement and &gt;=70% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP.</description>
        <time_frame>Week 2, 4, 6, 12, 14, 22 and 30 (pre-dose)</time_frame>
        <population>The ITT Population was defined as all participants who were randomized to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 1: PF-06438179</title>
            <description>Participants were scheduled to receive intravenous infusions of PF-06438179 at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Period 1: Infliximab-EU Remicade (INX)</title>
            <description>Participants were scheduled to receive intravenous infusions of INX at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1</title>
          <description>ACR50 response: &gt;=50% improvement in tender joint count, &gt;=50% improvement in swollen joint count improvement and &gt;=50% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP. ACR70 response: &gt;=70% improvement in tender joint count, &gt;=70% improvement in swollen joint count improvement and &gt;=70% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP.</description>
          <population>The ITT Population was defined as all participants who were randomized to study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR50 (Week 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 (Week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 (Week 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 (Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 (Week 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 (Week 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 (Week 30, pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 (Week 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 (Week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 (Week 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 (Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 (Week 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 (Week 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 (Week 30, pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2</title>
        <description>ACR50 response: &gt;=50% improvement in tender joint count, &gt;=50% improvement in swollen joint count improvement and &gt;=50% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP. ACR70 response: &gt;=70% improvement in tender joint count, &gt;=70% improvement in swollen joint count improvement and &gt;=70% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP.</description>
        <time_frame>Week 38, 46 and 54 (pre-dose)</time_frame>
        <population>The ITT Population was defined as all participants who were randomized to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2: PF-06438179/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of PF-06438179 in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O2">
            <title>Period 2: INX/INX</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive INX in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O3">
            <title>Period 2: INX/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2</title>
          <description>ACR50 response: &gt;=50% improvement in tender joint count, &gt;=50% improvement in swollen joint count improvement and &gt;=50% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP. ACR70 response: &gt;=70% improvement in tender joint count, &gt;=70% improvement in swollen joint count improvement and &gt;=70% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP.</description>
          <population>The ITT Population was defined as all participants who were randomized to study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR50 (Week 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 (Week 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 (Week 54, pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 (Week 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 (Week 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 (Week 54, pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3</title>
        <description>ACR50 response: &gt;=50% improvement in tender joint count, &gt;=50% improvement in swollen joint count improvement and &gt;=50% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP. ACR70 response: &gt;=70% improvement in tender joint count, &gt;=70% improvement in swollen joint count improvement and &gt;=70% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP.</description>
        <time_frame>Week 62, 70 and 78</time_frame>
        <population>The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 3: PF-06438179/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of PF-06438179 in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O2">
            <title>Period 3: INX/INX/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O3">
            <title>Period 3: INX/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and PF-06438179 in Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3</title>
          <description>ACR50 response: &gt;=50% improvement in tender joint count, &gt;=50% improvement in swollen joint count improvement and &gt;=50% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP. ACR70 response: &gt;=70% improvement in tender joint count, &gt;=70% improvement in swollen joint count improvement and &gt;=70% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP.</description>
          <population>The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR50 (Week 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 (Week 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 (Week 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 (Week 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 (Week 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 (Week 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1</title>
        <description>DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on visual analogue scale [VAS] from 0 to 100 mm; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) less than (&lt;)2.6=remission, &lt;3.2=low disease activity, &gt;=3.2-5.1=moderate disease activity and greater than (&gt;) 5.1=high disease activity. HAQ-DI assess degree of difficulty a participant experienced (past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.</description>
        <time_frame>Baseline (Day 1), Week 2, 4, 6, 12, 14, 22 and 30</time_frame>
        <population>The ITT Population was defined as all participants who were randomized to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 1: PF-06438179</title>
            <description>Participants were scheduled to receive intravenous infusions of PF-06438179 at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Period 1: Infliximab-EU Remicade (INX)</title>
            <description>Participants were scheduled to receive intravenous infusions of INX at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1</title>
          <description>DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on visual analogue scale [VAS] from 0 to 100 mm; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) less than (&lt;)2.6=remission, &lt;3.2=low disease activity, &gt;=3.2-5.1=moderate disease activity and greater than (&gt;) 5.1=high disease activity. HAQ-DI assess degree of difficulty a participant experienced (past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.</description>
          <population>The ITT Population was defined as all participants who were randomized to study treatment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28-CRP (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="325"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.950" spread="0.9577"/>
                    <measurement group_id="O2" value="5.983" spread="0.9210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP (Change at Week 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="318"/>
                    <count group_id="O2" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.213" spread="0.9280"/>
                    <measurement group_id="O2" value="-1.241" spread="0.8879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP (Change at Week 4)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="312"/>
                    <count group_id="O2" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.596" spread="1.1259"/>
                    <measurement group_id="O2" value="-1.605" spread="1.0881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP (Change at Week 6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="312"/>
                    <count group_id="O2" value="319"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.710" spread="1.1959"/>
                    <measurement group_id="O2" value="-1.750" spread="1.0885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP (Change at Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="310"/>
                    <count group_id="O2" value="316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.898" spread="1.3516"/>
                    <measurement group_id="O2" value="-1.885" spread="1.2142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP (Change at Week 14)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="310"/>
                    <count group_id="O2" value="314"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.901" spread="1.4125"/>
                    <measurement group_id="O2" value="-1.827" spread="1.3019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP (Change at Week 22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="301"/>
                    <count group_id="O2" value="307"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.005" spread="1.4236"/>
                    <measurement group_id="O2" value="-2.002" spread="1.2972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP (Change at Week 30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="292"/>
                    <count group_id="O2" value="297"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.140" spread="1.4197"/>
                    <measurement group_id="O2" value="-2.117" spread="1.2738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="325"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.623" spread="0.6485"/>
                    <measurement group_id="O2" value="1.586" spread="0.6490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI (Change at Week 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.317" spread="0.4100"/>
                    <measurement group_id="O2" value="-0.328" spread="0.4370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI (Change at Week 4)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="317"/>
                    <count group_id="O2" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.472" spread="0.4728"/>
                    <measurement group_id="O2" value="-0.477" spread="0.4861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI (Change at Week 6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="314"/>
                    <count group_id="O2" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.496" spread="0.5505"/>
                    <measurement group_id="O2" value="-0.520" spread="0.5022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI (Change at Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="311"/>
                    <count group_id="O2" value="318"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.535" spread="0.5795"/>
                    <measurement group_id="O2" value="-0.524" spread="0.5857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI (Change at Week 14)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="311"/>
                    <count group_id="O2" value="316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.572" spread="0.5910"/>
                    <measurement group_id="O2" value="-0.531" spread="0.5876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI (Change at Week 22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="301"/>
                    <count group_id="O2" value="311"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.588" spread="0.6061"/>
                    <measurement group_id="O2" value="-0.569" spread="0.5958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI (Change at Week 30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.621" spread="0.6484"/>
                    <measurement group_id="O2" value="-0.612" spread="0.6546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2</title>
        <description>DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on VAS from 0 to 100 millimeter [mm]; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) &lt;2.6=remission, &lt;3.2=low disease activity, &gt;=3.2-5.1=moderate disease activity and &gt;5.1=high disease activity. HAQ-DI assess degree of difficulty a participant experienced (past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.</description>
        <time_frame>Baseline (Week 30 pre-dose), Week 38, 46 and 54</time_frame>
        <population>The ITT Population was defined as all participants who were randomized to study treatment. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2: PF-06438179/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of PF-06438179 in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O2">
            <title>Period 2: INX/INX</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive INX in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O3">
            <title>Period 2: INX/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2</title>
          <description>DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on VAS from 0 to 100 millimeter [mm]; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) &lt;2.6=remission, &lt;3.2=low disease activity, &gt;=3.2-5.1=moderate disease activity and &gt;5.1=high disease activity. HAQ-DI assess degree of difficulty a participant experienced (past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.</description>
          <population>The ITT Population was defined as all participants who were randomized to study treatment. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28-CRP (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="278"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.765" spread="1.4629"/>
                    <measurement group_id="O2" value="3.819" spread="1.3624"/>
                    <measurement group_id="O3" value="3.781" spread="1.2547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP (Change at Week 38)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="276"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.181" spread="0.9574"/>
                    <measurement group_id="O2" value="0.036" spread="0.8686"/>
                    <measurement group_id="O3" value="-0.059" spread="0.8756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP (Change at Week 46)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.228" spread="1.0453"/>
                    <measurement group_id="O2" value="0.048" spread="1.2584"/>
                    <measurement group_id="O3" value="-0.017" spread="1.0692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP (Change at Week 54)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="256"/>
                    <count group_id="O2" value="129"/>
                    <count group_id="O3" value="128"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.275" spread="1.1338"/>
                    <measurement group_id="O2" value="-0.109" spread="1.1801"/>
                    <measurement group_id="O3" value="-0.057" spread="1.2339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI (Change at Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="278"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.978" spread="0.7042"/>
                    <measurement group_id="O2" value="0.913" spread="0.6634"/>
                    <measurement group_id="O3" value="0.951" spread="0.6481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI (Change at Week 38)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="277"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.019" spread="0.3328"/>
                    <measurement group_id="O2" value="0.019" spread="0.2889"/>
                    <measurement group_id="O3" value="0.007" spread="0.3688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI (Change at Week 46)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="269"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.043" spread="0.3774"/>
                    <measurement group_id="O2" value="0.014" spread="0.3823"/>
                    <measurement group_id="O3" value="0.035" spread="0.4325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI (Change at Week 54)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="259"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.026" spread="0.4407"/>
                    <measurement group_id="O2" value="0.017" spread="0.4399"/>
                    <measurement group_id="O3" value="-0.044" spread="0.3881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3</title>
        <description>DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on VAS from 0 to 100 mm; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) &lt;2.6=remission, &lt;3.2=low disease activity, &gt;=3.2-5.1=moderate disease activity and &gt;5.1=high disease activity. HAQ-DI assess degree of difficulty a participant experienced (past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.</description>
        <time_frame>Baseline (Week 54 pre-dose), Week 62, 70 and 78</time_frame>
        <population>The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 3: PF-06438179/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of PF-06438179 in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O2">
            <title>Period 3: INX/INX/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O3">
            <title>Period 3: INX/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and PF-06438179 in Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3</title>
          <description>DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on VAS from 0 to 100 mm; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) &lt;2.6=remission, &lt;3.2=low disease activity, &gt;=3.2-5.1=moderate disease activity and &gt;5.1=high disease activity. HAQ-DI assess degree of difficulty a participant experienced (past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.</description>
          <population>The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28-CRP (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.386" spread="1.3229"/>
                    <measurement group_id="O2" value="3.561" spread="1.3123"/>
                    <measurement group_id="O3" value="3.594" spread="1.2572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP (Change at Week 62)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.072" spread="0.9150"/>
                    <measurement group_id="O2" value="-0.004" spread="0.8190"/>
                    <measurement group_id="O3" value="-0.154" spread="0.6840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP (Change at Week 70)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.157" spread="0.9502"/>
                    <measurement group_id="O2" value="-0.168" spread="0.8421"/>
                    <measurement group_id="O3" value="-0.162" spread="0.7970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP (Change at Week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="114"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.236" spread="1.0361"/>
                    <measurement group_id="O2" value="-0.269" spread="0.9759"/>
                    <measurement group_id="O3" value="-0.215" spread="1.0584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.905" spread="0.7050"/>
                    <measurement group_id="O2" value="0.893" spread="0.6691"/>
                    <measurement group_id="O3" value="0.883" spread="0.6109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI (Change at Week 62)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.024" spread="0.3126"/>
                    <measurement group_id="O2" value="0.021" spread="0.2989"/>
                    <measurement group_id="O3" value="0.008" spread="0.2942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI (Change at Week 70)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.046" spread="0.3502"/>
                    <measurement group_id="O2" value="-0.027" spread="0.2758"/>
                    <measurement group_id="O3" value="0.030" spread="0.2950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI (Change at Week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="116"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.079" spread="0.3869"/>
                    <measurement group_id="O2" value="-0.022" spread="0.3521"/>
                    <measurement group_id="O3" value="0.001" spread="0.3800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS &lt;2.6) Remission: Period 1</title>
        <description>ACR/EULAR remission was considered if the scores on tender joint count, swollen joint count, hs-CRP (mg/dL), and patient's global assessment of arthritis (PGA) all were less than or equal to (=&lt;) 1 or the score on the simplified disease activity index (SDAI) was =&lt;3.3. SDAI was calculated as the sum of number of tender and swollen joint count (using 28 joints), PGA, physician global assessment, and CRP (mg/dL). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. Physician global assessment was recorded on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicated more disease activity. DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, CRP (mg/dL) and PGA using a 10 mm-VAS from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. DAS28 &lt;3.2: low disease activity, DAS28 &lt;2.6: remission.</description>
        <time_frame>Week 2, 4, 6, 12, 14, 22 and Week 30 (pre-dose)</time_frame>
        <population>The ITT Population was defined as all participants who were randomized to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 1: PF-06438179</title>
            <description>Participants were scheduled to receive intravenous infusions of PF-06438179 at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Period 1: Infliximab-EU Remicade (INX)</title>
            <description>Participants were scheduled to receive intravenous infusions of INX at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS &lt;2.6) Remission: Period 1</title>
          <description>ACR/EULAR remission was considered if the scores on tender joint count, swollen joint count, hs-CRP (mg/dL), and patient's global assessment of arthritis (PGA) all were less than or equal to (=&lt;) 1 or the score on the simplified disease activity index (SDAI) was =&lt;3.3. SDAI was calculated as the sum of number of tender and swollen joint count (using 28 joints), PGA, physician global assessment, and CRP (mg/dL). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. Physician global assessment was recorded on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicated more disease activity. DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, CRP (mg/dL) and PGA using a 10 mm-VAS from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. DAS28 &lt;3.2: low disease activity, DAS28 &lt;2.6: remission.</description>
          <population>The ITT Population was defined as all participants who were randomized to study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR/EULAR remission (Week 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR/EULAR remission (Week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR/EULAR remission (Week 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR/EULAR remission (Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR/EULAR remission (Week 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR/EULAR remission (Week 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR/EULAR remission (Week 30, pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS remission (Week 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS remission (Week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS remission (Week 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS remission (Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS remission (Week 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS remission (Week 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS remission (Week 30, pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS &lt;2.6) Remission: Period 2</title>
        <description>ACR/EULAR remission was considered if the scores on tender joint count, swollen joint count, hs-CRP (mg/dL), and PGA all were =&lt;1 or the score on the SDAI was =&lt;3.3. SDAI was calculated as the sum of number of tender and swollen joint count (using 28 joints), PGA, physician global assessment, and CRP (mg/dL). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. Physician global assessment was recorded on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicated more disease activity. DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, CRP (mg/dL) and PGA using a 10 mm-VAS from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. DAS28 &lt;3.2: low disease activity, DAS28 &lt;2.6: remission.</description>
        <time_frame>Week 38, 46 and 54 (pre-dose)</time_frame>
        <population>The ITT Population was defined as all participants who were randomized to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2: PF-06438179/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of PF-06438179 in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O2">
            <title>Period 2: INX/INX</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive INX in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O3">
            <title>Period 2: INX/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS &lt;2.6) Remission: Period 2</title>
          <description>ACR/EULAR remission was considered if the scores on tender joint count, swollen joint count, hs-CRP (mg/dL), and PGA all were =&lt;1 or the score on the SDAI was =&lt;3.3. SDAI was calculated as the sum of number of tender and swollen joint count (using 28 joints), PGA, physician global assessment, and CRP (mg/dL). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. Physician global assessment was recorded on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicated more disease activity. DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, CRP (mg/dL) and PGA using a 10 mm-VAS from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. DAS28 &lt;3.2: low disease activity, DAS28 &lt;2.6: remission.</description>
          <population>The ITT Population was defined as all participants who were randomized to study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR/EULAR remission (Week 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR/EULAR remission (Week 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR/EULAR remission (Week 54, pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS remission (Week 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS remission (Week 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS remission (Week 54, pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS &lt;2.6) Remission: Period 3</title>
        <description>ACR/EULAR remission was considered if the scores on tender joint count, swollen joint count, hs-CRP (mg/dL), and PGA all were =&lt;1 or the score on the SDAI was =&lt;3.3. SDAI was calculated as the sum of number of tender and swollen joint count (using 28 joints), PGA, physician global assessment, and CRP (mg/dL). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. Physician global assessment was recorded on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicated more disease activity. DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, CRP (mg/dL) and PGA using a 10 mm-VAS from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. DAS28 &lt;3.2: low disease activity, DAS28 &lt;2.6: remission.</description>
        <time_frame>Week 62, 70 and 78</time_frame>
        <population>The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 3: PF-06438179/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of PF-06438179 in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O2">
            <title>Period 3: INX/INX/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O3">
            <title>Period 3: INX/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and PF-06438179 in Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS &lt;2.6) Remission: Period 3</title>
          <description>ACR/EULAR remission was considered if the scores on tender joint count, swollen joint count, hs-CRP (mg/dL), and PGA all were =&lt;1 or the score on the SDAI was =&lt;3.3. SDAI was calculated as the sum of number of tender and swollen joint count (using 28 joints), PGA, physician global assessment, and CRP (mg/dL). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. Physician global assessment was recorded on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicated more disease activity. DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, CRP (mg/dL) and PGA using a 10 mm-VAS from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. DAS28 &lt;3.2: low disease activity, DAS28 &lt;2.6: remission.</description>
          <population>The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR/EULAR remission (Week 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR/EULAR remission (Week 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR/EULAR remission (Week 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS remission (Week 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS remission (Week 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS remission (Week 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1</title>
        <description>EULAR response was based on DAS28 EULAR response criteria which was defined as good response = DAS28 change of &gt;1.2 with DAS28 =&lt;3.2; moderate response = DAS28 change of &gt;0.6 to =&lt;1.2 with DAS28 &gt;3.2-5.1 and no-response = DAS28 change of =&lt;0.6 with DAS28 &gt;5.1.</description>
        <time_frame>Week 2, 4, 6, 12, 14, 22 and Week 30 (pre-dose)</time_frame>
        <population>The ITT Population was defined as all participants who were randomized to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 1: PF-06438179</title>
            <description>Participants were scheduled to receive intravenous infusions of PF-06438179 at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Period 1: Infliximab-EU Remicade (INX)</title>
            <description>Participants were scheduled to receive intravenous infusions of INX at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1</title>
          <description>EULAR response was based on DAS28 EULAR response criteria which was defined as good response = DAS28 change of &gt;1.2 with DAS28 =&lt;3.2; moderate response = DAS28 change of &gt;0.6 to =&lt;1.2 with DAS28 &gt;3.2-5.1 and no-response = DAS28 change of =&lt;0.6 with DAS28 &gt;5.1.</description>
          <population>The ITT Population was defined as all participants who were randomized to study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (good response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="317"/>
                    <count group_id="O2" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (moderate response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="317"/>
                    <count group_id="O2" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172"/>
                    <measurement group_id="O2" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (no response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="317"/>
                    <count group_id="O2" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (good response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="312"/>
                    <count group_id="O2" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (moderate response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="312"/>
                    <count group_id="O2" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (no response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="312"/>
                    <count group_id="O2" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (good response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="312"/>
                    <count group_id="O2" value="319"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (moderate response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="312"/>
                    <count group_id="O2" value="319"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (no response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="312"/>
                    <count group_id="O2" value="319"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (good response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="310"/>
                    <count group_id="O2" value="316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (moderate response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="310"/>
                    <count group_id="O2" value="316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (no response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="310"/>
                    <count group_id="O2" value="316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (good response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="310"/>
                    <count group_id="O2" value="314"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (moderate response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="310"/>
                    <count group_id="O2" value="314"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (no response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="310"/>
                    <count group_id="O2" value="314"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 22 (good response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="301"/>
                    <count group_id="O2" value="307"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 22 (moderate response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="301"/>
                    <count group_id="O2" value="307"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 22 (no response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="301"/>
                    <count group_id="O2" value="307"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (good response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="292"/>
                    <count group_id="O2" value="297"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (moderate response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="292"/>
                    <count group_id="O2" value="297"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (no response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="292"/>
                    <count group_id="O2" value="297"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2</title>
        <description>EULAR response was based on DAS28 EULAR response criteria which was defined as good response = DAS28 change of &gt;1.2 with DAS28 =&lt;3.2; moderate response = DAS28 change of &gt;0.6 to =&lt;1.2 with DAS28 &gt;3.2-5.1 and no-response = DAS28 change of =&lt;0.6 with DAS28 &gt;5.1.</description>
        <time_frame>Week 38, 46 and Week 54 (pre-dose)</time_frame>
        <population>The ITT Population was defined as all participants who were randomized to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2: PF-06438179/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of PF-06438179 in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O2">
            <title>Period 2: INX/INX</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive INX in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O3">
            <title>Period 2: INX/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2</title>
          <description>EULAR response was based on DAS28 EULAR response criteria which was defined as good response = DAS28 change of &gt;1.2 with DAS28 =&lt;3.2; moderate response = DAS28 change of &gt;0.6 to =&lt;1.2 with DAS28 &gt;3.2-5.1 and no-response = DAS28 change of =&lt;0.6 with DAS28 &gt;5.1.</description>
          <population>The ITT Population was defined as all participants who were randomized to study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 38 (good response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="276"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 38 (moderate response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="276"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 38 (no response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="276"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 46 (good response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 46 (moderate response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 46 (no response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54 (good response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="256"/>
                    <count group_id="O2" value="129"/>
                    <count group_id="O3" value="128"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54 (moderate response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="256"/>
                    <count group_id="O2" value="129"/>
                    <count group_id="O3" value="128"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54 (no response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="256"/>
                    <count group_id="O2" value="129"/>
                    <count group_id="O3" value="128"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3</title>
        <description>EULAR response was based on DAS28 EULAR response criteria which was defined as good response = DAS28 change of &gt;1.2 with DAS28 =&lt;3.2; moderate response = DAS28 change of &gt;0.6 to =&lt;1.2 with DAS28 &gt;3.2-5.1 and no-response = DAS28 change of =&lt;0.6 with DAS28 &gt;5.1.</description>
        <time_frame>Week 62, 70 and Week 78</time_frame>
        <population>The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 3: PF-06438179/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of PF-06438179 in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O2">
            <title>Period 3: INX/INX/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O3">
            <title>Period 3: INX/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and PF-06438179 in Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3</title>
          <description>EULAR response was based on DAS28 EULAR response criteria which was defined as good response = DAS28 change of &gt;1.2 with DAS28 =&lt;3.2; moderate response = DAS28 change of &gt;0.6 to =&lt;1.2 with DAS28 &gt;3.2-5.1 and no-response = DAS28 change of =&lt;0.6 with DAS28 &gt;5.1.</description>
          <population>The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 62 (good response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 62 (moderate response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 62 (no response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 70 (good response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 70 (moderate response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 70 (no response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78 (good response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="114"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78 (moderate response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="114"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78 (no response)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="114"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 1</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Week 30 that were absent before treatment or that worsened relative to pre-treatment state. Treatment-related TEAE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non-serious adverse events.</description>
        <time_frame>Baseline (Day 1) up to Week 30</time_frame>
        <population>Safety population was defined as all participants who were randomized and received at least 1 dose of study treatment, analyzed by actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 1: PF-06438179</title>
            <description>Participants were scheduled to receive intravenous infusions of PF-06438179 at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Period 1: Infliximab-EU Remicade (INX)</title>
            <description>Participants were scheduled to receive intravenous infusions of INX at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 1</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Week 30 that were absent before treatment or that worsened relative to pre-treatment state. Treatment-related TEAE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non-serious adverse events.</description>
          <population>Safety population was defined as all participants who were randomized and received at least 1 dose of study treatment, analyzed by actual treatment received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 2</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Week 54 that were absent before treatment or that worsened relative to pre-treatment state. Treatment-related TEAE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non-serious adverse events.</description>
        <time_frame>Baseline (Week 30 pre-dose) up to Week 54</time_frame>
        <population>Safety population was defined as all participants who were randomized and received at least 1 dose of study treatment, analyzed by actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2: PF-06438179/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of PF-06438179 in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O2">
            <title>Period 2: INX/INX</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive INX in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O3">
            <title>Period 2: INX/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 2</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Week 54 that were absent before treatment or that worsened relative to pre-treatment state. Treatment-related TEAE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non-serious adverse events.</description>
          <population>Safety population was defined as all participants who were randomized and received at least 1 dose of study treatment, analyzed by actual treatment received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 3</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Week 78 that were absent before treatment or that worsened relative to pre-treatment state. Treatment-related TEAE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non-serious adverse events.</description>
        <time_frame>Baseline (Week 54 pre-dose) up to Week 78</time_frame>
        <population>Safety population was defined as all participants who were randomized and received at least 1 dose of study treatment, analyzed by actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 3: PF-06438179/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of PF-06438179 in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O2">
            <title>Period 3: INX/INX/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O3">
            <title>Period 3: INX/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and PF-06438179 in Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 3</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Week 78 that were absent before treatment or that worsened relative to pre-treatment state. Treatment-related TEAE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non-serious adverse events.</description>
          <population>Safety population was defined as all participants who were randomized and received at least 1 dose of study treatment, analyzed by actual treatment received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) of Grade 3 or Higher Severity: Period 1</title>
        <description>AEs were graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) Version 4.03 as Grades 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life threatening AEs and Grade 5= death related to AE. AEs of Grade 3 and higher severity are reported in this outcome measure.</description>
        <time_frame>Baseline (Day 1) up to Week 30</time_frame>
        <population>Safety population was defined as all participants who were randomized and received at least 1 dose of study treatment, analyzed by actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 1: PF-06438179</title>
            <description>Participants were scheduled to receive intravenous infusions of PF-06438179 at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Period 1: Infliximab-EU Remicade (INX)</title>
            <description>Participants were scheduled to receive intravenous infusions of INX at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) of Grade 3 or Higher Severity: Period 1</title>
          <description>AEs were graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) Version 4.03 as Grades 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life threatening AEs and Grade 5= death related to AE. AEs of Grade 3 and higher severity are reported in this outcome measure.</description>
          <population>Safety population was defined as all participants who were randomized and received at least 1 dose of study treatment, analyzed by actual treatment received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs (Grade 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs (Grade 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs (Grade 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) of Grade 3 or Higher Severity: Period 2</title>
        <description>AEs were graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) Version 4.03 as Grades 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life threatening AEs and Grade 5= death related to AE. AEs of Grade 3 and higher severity are reported in this outcome measure.</description>
        <time_frame>Baseline (Week 30 pre-dose) up to Week 54</time_frame>
        <population>Safety population was defined as all participants who were randomized and received at least 1 dose of study treatment, analyzed by actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2: PF-06438179/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of PF-06438179 in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O2">
            <title>Period 2: INX/INX</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive INX in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O3">
            <title>Period 2: INX/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) of Grade 3 or Higher Severity: Period 2</title>
          <description>AEs were graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) Version 4.03 as Grades 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life threatening AEs and Grade 5= death related to AE. AEs of Grade 3 and higher severity are reported in this outcome measure.</description>
          <population>Safety population was defined as all participants who were randomized and received at least 1 dose of study treatment, analyzed by actual treatment received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs (Grade 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs (Grade 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs (Grade 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) of Grade 3 or Higher Severity: Period 3</title>
        <description>AEs were graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) Version 4.03 as Grades 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life threatening AEs and Grade 5= death related to AE. AEs of Grade 3 and higher severity are reported in this outcome measure.</description>
        <time_frame>Baseline (Week 54 pre-dose) up to Week 78</time_frame>
        <population>Safety population was defined as all participants who were randomized and received at least 1 dose of study treatment, analyzed by actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 3: PF-06438179/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of PF-06438179 in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O2">
            <title>Period 3: INX/INX/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O3">
            <title>Period 3: INX/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and PF-06438179 in Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) of Grade 3 or Higher Severity: Period 3</title>
          <description>AEs were graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) Version 4.03 as Grades 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life threatening AEs and Grade 5= death related to AE. AEs of Grade 3 and higher severity are reported in this outcome measure.</description>
          <population>Safety population was defined as all participants who were randomized and received at least 1 dose of study treatment, analyzed by actual treatment received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs (Grade 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs (Grade 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs (Grade 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Laboratory Abnormalities: Period 1</title>
        <description>Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count, lymphocytes, neutrophils: &lt;0.8*lower limit of normal (LLN); platelets: &gt;1.75*upper limit of normal (ULN); white blood cell count: &lt;0.6*LLN; basophils, eosinophils, monocytes: &gt;1.2*ULN. liver function: bilirubin: &gt;1.5*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: &gt;3.0*ULN; protein, albumin: &lt;0.8*LLN&gt;&lt;/0&gt;1.2*ULN; renal function:blood urea nitrogen,creatinine: &gt;1.3*ULN; uric acid: &gt;1.2*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: &lt;0.9*LLN,&gt;1.1*ULN; urinalysis: pH&lt;4.5, &gt;8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: &lt;0.6*LLN,&gt;1.5*ULN). Participants with any laboratory abnormality in Period 1 were reported in this outcome measure.</description>
        <time_frame>Baseline (Day 1) up to Week 30</time_frame>
        <population>Safety population was defined as all participants who are randomized and receive at least 1 dose of study treatment, analyzed by actual treatment received. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 1: PF-06438179</title>
            <description>Participants were scheduled to receive intravenous infusions of PF-06438179 at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Period 1: Infliximab-EU Remicade (INX)</title>
            <description>Participants were scheduled to receive intravenous infusions of INX at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Abnormalities: Period 1</title>
          <description>Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count, lymphocytes, neutrophils: &lt;0.8*lower limit of normal (LLN); platelets: &gt;1.75*upper limit of normal (ULN); white blood cell count: &lt;0.6*LLN; basophils, eosinophils, monocytes: &gt;1.2*ULN. liver function: bilirubin: &gt;1.5*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: &gt;3.0*ULN; protein, albumin: &lt;0.8*LLN&gt;&lt;/0&gt;1.2*ULN; renal function:blood urea nitrogen,creatinine: &gt;1.3*ULN; uric acid: &gt;1.2*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: &lt;0.9*LLN,&gt;1.1*ULN; urinalysis: pH&lt;4.5, &gt;8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: &lt;0.6*LLN,&gt;1.5*ULN). Participants with any laboratory abnormality in Period 1 were reported in this outcome measure.</description>
          <population>Safety population was defined as all participants who are randomized and receive at least 1 dose of study treatment, analyzed by actual treatment received. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                    <measurement group_id="O2" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Laboratory Abnormalities: Period 2</title>
        <description>Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count, lymphocytes, neutrophils: &lt;0.8*lower limit of normal (LLN); platelets: &gt;1.75*upper limit of normal (ULN); white blood cell count: &lt;0.6*LLN; basophils, eosinophils, monocytes: &gt;1.2*ULN. liver function: bilirubin: &gt;1.5*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: &gt;3.0*ULN; protein, albumin: &lt;0.8*LLN&gt;&lt;/0&gt;1.2*ULN; renal function:blood urea nitrogen,creatinine: &gt;1.3*ULN; uric acid: &gt;1.2*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: &lt;0.9*LLN,&gt;1.1*ULN; urinalysis: pH&lt;4.5, &gt;8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: &lt;0.6*LLN,&gt;1.5*ULN). Participants with any laboratory abnormality in Period 2 were reported in this outcome measure.</description>
        <time_frame>Baseline (Week 30 pre-dose) up to Week 54</time_frame>
        <population>Safety population was defined as all participants who are randomized and receive at least 1 dose of study treatment, analyzed by actual treatment received. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2: PF-06438179/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of PF-06438179 in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O2">
            <title>Period 2: INX/INX</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive INX in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O3">
            <title>Period 2: INX/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Abnormalities: Period 2</title>
          <description>Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count, lymphocytes, neutrophils: &lt;0.8*lower limit of normal (LLN); platelets: &gt;1.75*upper limit of normal (ULN); white blood cell count: &lt;0.6*LLN; basophils, eosinophils, monocytes: &gt;1.2*ULN. liver function: bilirubin: &gt;1.5*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: &gt;3.0*ULN; protein, albumin: &lt;0.8*LLN&gt;&lt;/0&gt;1.2*ULN; renal function:blood urea nitrogen,creatinine: &gt;1.3*ULN; uric acid: &gt;1.2*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: &lt;0.9*LLN,&gt;1.1*ULN; urinalysis: pH&lt;4.5, &gt;8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: &lt;0.6*LLN,&gt;1.5*ULN). Participants with any laboratory abnormality in Period 2 were reported in this outcome measure.</description>
          <population>Safety population was defined as all participants who are randomized and receive at least 1 dose of study treatment, analyzed by actual treatment received. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Laboratory Abnormalities: Period 3</title>
        <description>Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count, lymphocytes, neutrophils: &lt;0.8*lower limit of normal (LLN); platelets: &gt;1.75*upper limit of normal (ULN); white blood cell count: &lt;0.6*LLN; basophils, eosinophils, monocytes: &gt;1.2*ULN. liver function: bilirubin: &gt;1.5*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: &gt;3.0*ULN; protein, albumin: &lt;0.8*LLN&gt;&lt;/0&gt;1.2*ULN; renal function:blood urea nitrogen,creatinine: &gt;1.3*ULN; uric acid: &gt;1.2*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: &lt;0.9*LLN,&gt;1.1*ULN; urinalysis: pH&lt;4.5, &gt;8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: &lt;0.6*LLN,&gt;1.5*ULN). Participants with any laboratory abnormality in Period 3 were reported in this outcome measure.</description>
        <time_frame>Baseline (Week 54 pre-dose) up to Week 78</time_frame>
        <population>Safety population was defined as all participants who are randomized and receive at least 1 dose of study treatment, analyzed by actual treatment received. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 3: PF-06438179/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of PF-06438179 in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O2">
            <title>Period 3: INX/INX/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O3">
            <title>Period 3: INX/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and PF-06438179 in Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Abnormalities: Period 3</title>
          <description>Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count, lymphocytes, neutrophils: &lt;0.8*lower limit of normal (LLN); platelets: &gt;1.75*upper limit of normal (ULN); white blood cell count: &lt;0.6*LLN; basophils, eosinophils, monocytes: &gt;1.2*ULN. liver function: bilirubin: &gt;1.5*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: &gt;3.0*ULN; protein, albumin: &lt;0.8*LLN&gt;&lt;/0&gt;1.2*ULN; renal function:blood urea nitrogen,creatinine: &gt;1.3*ULN; uric acid: &gt;1.2*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: &lt;0.9*LLN,&gt;1.1*ULN; urinalysis: pH&lt;4.5, &gt;8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: &lt;0.6*LLN,&gt;1.5*ULN). Participants with any laboratory abnormality in Period 3 were reported in this outcome measure.</description>
          <population>Safety population was defined as all participants who are randomized and receive at least 1 dose of study treatment, analyzed by actual treatment received. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1</title>
        <description>Tender joint count was an assessment of 68 joints (upper body, upper extremity, and lower extremity). Each joint's response to pressure/motion was assessed as: Present or Absent. Swollen joint count was an assessment of 66 joints (upper body, upper extremity, and lower extremity). Each joint was assessed for swelling as: Present or Absent.</description>
        <time_frame>Baseline (Day 1), Week 2, 4, 6, 12, 14, 22 and Week 30</time_frame>
        <population>The ITT Population was defined as all participants who were randomized to study treatment. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 1: PF-06438179</title>
            <description>Participants were scheduled to receive intravenous infusions of PF-06438179 at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Period 1: Infliximab-EU Remicade (INX)</title>
            <description>Participants were scheduled to receive intravenous infusions of INX at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1</title>
          <description>Tender joint count was an assessment of 68 joints (upper body, upper extremity, and lower extremity). Each joint's response to pressure/motion was assessed as: Present or Absent. Swollen joint count was an assessment of 66 joints (upper body, upper extremity, and lower extremity). Each joint was assessed for swelling as: Present or Absent.</description>
          <population>The ITT Population was defined as all participants who were randomized to study treatment. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
          <units>joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tender joint count (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="325"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" spread="13.90"/>
                    <measurement group_id="O2" value="25.8" spread="12.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender joint count (Change at Week 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="8.78"/>
                    <measurement group_id="O2" value="-7.5" spread="8.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender joint count (Change at Week 4)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="317"/>
                    <count group_id="O2" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.5" spread="10.02"/>
                    <measurement group_id="O2" value="-10.4" spread="9.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender joint count (Change at Week 6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="313"/>
                    <count group_id="O2" value="319"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.6" spread="11.17"/>
                    <measurement group_id="O2" value="-12.1" spread="10.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender joint count (Change at Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="311"/>
                    <count group_id="O2" value="318"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.1" spread="11.84"/>
                    <measurement group_id="O2" value="-13.2" spread="11.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender joint count (Change at Week 14)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="311"/>
                    <count group_id="O2" value="316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="12.50"/>
                    <measurement group_id="O2" value="-13.0" spread="12.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender joint count (Change at Week 22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="301"/>
                    <count group_id="O2" value="311"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.2" spread="12.62"/>
                    <measurement group_id="O2" value="-15.2" spread="12.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender joint count (Change at Week 30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.4" spread="13.19"/>
                    <measurement group_id="O2" value="-15.6" spread="12.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen joint count (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="325"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="9.44"/>
                    <measurement group_id="O2" value="16.3" spread="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen joint count (Change at Week 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="6.89"/>
                    <measurement group_id="O2" value="-5.7" spread="7.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen joint count (Change at Week 4)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="317"/>
                    <count group_id="O2" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="7.75"/>
                    <measurement group_id="O2" value="-7.9" spread="7.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen joint count (Change at Week 6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="313"/>
                    <count group_id="O2" value="319"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="7.99"/>
                    <measurement group_id="O2" value="-9.0" spread="7.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen joint count (Change at Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="311"/>
                    <count group_id="O2" value="318"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="8.61"/>
                    <measurement group_id="O2" value="-9.6" spread="8.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen joint count (Change at Week 14)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="311"/>
                    <count group_id="O2" value="316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.3" spread="8.87"/>
                    <measurement group_id="O2" value="-9.6" spread="8.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen joint count (Change at Week 22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="301"/>
                    <count group_id="O2" value="311"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.5" spread="8.77"/>
                    <measurement group_id="O2" value="-10.2" spread="7.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen joint count (Change at Week 30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.0" spread="9.33"/>
                    <measurement group_id="O2" value="-10.7" spread="8.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2</title>
        <description>Tender joint count was an assessment of 68 joints (upper body, upper extremity, and lower extremity). Each joint's response to pressure/motion was assessed as: Present or Absent. Swollen joint count was an assessment of 66 joints (upper body, upper extremity, and lower extremity). Each joint was assessed for swelling as: Present or Absent.</description>
        <time_frame>Baseline (Week 30 pre-dose), Week 38, 46 and Week 54</time_frame>
        <population>The ITT Population was defined as all participants who were randomized to study treatment. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2: PF-06438179/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of PF-06438179 in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O2">
            <title>Period 2: INX/INX</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive INX in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O3">
            <title>Period 2: INX/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2</title>
          <description>Tender joint count was an assessment of 68 joints (upper body, upper extremity, and lower extremity). Each joint's response to pressure/motion was assessed as: Present or Absent. Swollen joint count was an assessment of 66 joints (upper body, upper extremity, and lower extremity). Each joint was assessed for swelling as: Present or Absent.</description>
          <population>The ITT Population was defined as all participants who were randomized to study treatment. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
          <units>joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tender joint count (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="278"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="11.74"/>
                    <measurement group_id="O2" value="10.2" spread="11.96"/>
                    <measurement group_id="O3" value="9.1" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender joint count (Change at Week 38)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="277"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="6.74"/>
                    <measurement group_id="O2" value="-0.5" spread="8.86"/>
                    <measurement group_id="O3" value="-1.0" spread="6.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender joint count (Change at Week 46)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="269"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="7.87"/>
                    <measurement group_id="O2" value="-1.0" spread="9.32"/>
                    <measurement group_id="O3" value="-0.8" spread="7.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender joint count (Change at Week 54)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="7.96"/>
                    <measurement group_id="O2" value="-1.7" spread="10.23"/>
                    <measurement group_id="O3" value="-0.5" spread="9.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen joint count (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="278"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="6.46"/>
                    <measurement group_id="O2" value="5.3" spread="6.57"/>
                    <measurement group_id="O3" value="4.6" spread="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen joint count (Change at Week 38)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="277"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="4.19"/>
                    <measurement group_id="O2" value="-0.1" spread="4.90"/>
                    <measurement group_id="O3" value="-0.3" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen joint count (Change at Week 46)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="269"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="5.20"/>
                    <measurement group_id="O2" value="0.0" spread="5.54"/>
                    <measurement group_id="O3" value="-0.5" spread="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen joint count (Change at Week 54)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="5.52"/>
                    <measurement group_id="O2" value="-0.9" spread="7.02"/>
                    <measurement group_id="O3" value="-0.7" spread="4.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3</title>
        <description>Tender joint count was an assessment of 68 joints (upper body, upper extremity, and lower extremity). Each joint's response to pressure/motion was assessed as: Present or Absent. Swollen joint count was an assessment of 66 joints (upper body, upper extremity, and lower extremity). Each joint was assessed for swelling as: Present or Absent.</description>
        <time_frame>Baseline (Week 54 pre-dose), Week 62, 70 and 78</time_frame>
        <population>The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 3: PF-06438179/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of PF-06438179 in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O2">
            <title>Period 3: INX/INX/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O3">
            <title>Period 3: INX/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and PF-06438179 in Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3</title>
          <description>Tender joint count was an assessment of 68 joints (upper body, upper extremity, and lower extremity). Each joint's response to pressure/motion was assessed as: Present or Absent. Swollen joint count was an assessment of 66 joints (upper body, upper extremity, and lower extremity). Each joint was assessed for swelling as: Present or Absent.</description>
          <population>The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
          <units>joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tender joint count (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="9.51"/>
                    <measurement group_id="O2" value="7.5" spread="9.21"/>
                    <measurement group_id="O3" value="7.4" spread="7.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender joint count (Change at Week 62)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="5.88"/>
                    <measurement group_id="O2" value="0.3" spread="5.21"/>
                    <measurement group_id="O3" value="-0.8" spread="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender joint count (Change at Week 70)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="6.32"/>
                    <measurement group_id="O2" value="-0.6" spread="5.14"/>
                    <measurement group_id="O3" value="-1.0" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender joint count (Change at Week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="116"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="6.57"/>
                    <measurement group_id="O2" value="-1.0" spread="5.82"/>
                    <measurement group_id="O3" value="-1.4" spread="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen joint count (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="5.72"/>
                    <measurement group_id="O2" value="4.1" spread="5.16"/>
                    <measurement group_id="O3" value="3.5" spread="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen joint count (Change at Week 62)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="3.76"/>
                    <measurement group_id="O2" value="0.0" spread="4.41"/>
                    <measurement group_id="O3" value="-0.3" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen joint count (Change at Week 70)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="4.60"/>
                    <measurement group_id="O2" value="-0.4" spread="4.12"/>
                    <measurement group_id="O3" value="-0.5" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen joint count (Change at Week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="116"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="4.63"/>
                    <measurement group_id="O2" value="-0.5" spread="4.00"/>
                    <measurement group_id="O3" value="-0.2" spread="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1</title>
        <description>PAAP: Participants assessed the severity of their arthritis pain by using a 100 mm VAS ranging from 0 (no pain) to 100 (most severe pain), which corresponded to the magnitude of their pain, where higher scores indicated more pain. PGA: Participants were asked the following question, &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; and their response was recorded on a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated worse health condition. PGAA: Participants were assessed how their overall arthritis appears at the time of the visit. The evaluation was based on the participant's disease signs, functional capacity and physical examination, and was independent of the PAAP and PGA assessments. The physician's response was recorded using a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated more disease activity.</description>
        <time_frame>Baseline (Day 1), Week 2, 4, 6, 12, 14, 22 and 30</time_frame>
        <population>The ITT Population was defined as all participants who were randomized to study treatment. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 1: PF-06438179</title>
            <description>Participants were scheduled to receive intravenous infusions of PF-06438179 at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Period 1: Infliximab-EU Remicade (INX)</title>
            <description>Participants were scheduled to receive intravenous infusions of INX at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1</title>
          <description>PAAP: Participants assessed the severity of their arthritis pain by using a 100 mm VAS ranging from 0 (no pain) to 100 (most severe pain), which corresponded to the magnitude of their pain, where higher scores indicated more pain. PGA: Participants were asked the following question, &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; and their response was recorded on a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated worse health condition. PGAA: Participants were assessed how their overall arthritis appears at the time of the visit. The evaluation was based on the participant's disease signs, functional capacity and physical examination, and was independent of the PAAP and PGA assessments. The physician's response was recorded using a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated more disease activity.</description>
          <population>The ITT Population was defined as all participants who were randomized to study treatment. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PAAP (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="325"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.514" spread="20.5903"/>
                    <measurement group_id="O2" value="63.098" spread="21.5442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAAP (Change at Week 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.724" spread="21.9589"/>
                    <measurement group_id="O2" value="-15.360" spread="19.4328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAAP (Change at Week 4)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="317"/>
                    <count group_id="O2" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.609" spread="22.3825"/>
                    <measurement group_id="O2" value="-20.552" spread="21.2670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAAP (Change at Week 6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="314"/>
                    <count group_id="O2" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.917" spread="25.0213"/>
                    <measurement group_id="O2" value="-22.797" spread="22.9133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAAP (Change at Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="311"/>
                    <count group_id="O2" value="318"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.364" spread="25.6602"/>
                    <measurement group_id="O2" value="-25.829" spread="24.8304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAAP (Change at Week 14)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="311"/>
                    <count group_id="O2" value="316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.131" spread="26.8712"/>
                    <measurement group_id="O2" value="-25.077" spread="25.0536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAAP (Change at week 22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="301"/>
                    <count group_id="O2" value="311"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.844" spread="27.0039"/>
                    <measurement group_id="O2" value="-25.788" spread="25.3225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAAP (Change at Week 30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.150" spread="27.9802"/>
                    <measurement group_id="O2" value="-28.853" spread="26.7252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="325"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.340" spread="20.7209"/>
                    <measurement group_id="O2" value="63.752" spread="22.9105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA (Change at Week 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.262" spread="22.8767"/>
                    <measurement group_id="O2" value="-16.504" spread="20.3188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA (Change at Week 4)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="317"/>
                    <count group_id="O2" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.393" spread="23.3769"/>
                    <measurement group_id="O2" value="-21.355" spread="23.6005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA (Change at Week 6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="314"/>
                    <count group_id="O2" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.536" spread="24.8041"/>
                    <measurement group_id="O2" value="-23.314" spread="24.2005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA (Change at Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="311"/>
                    <count group_id="O2" value="317"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.882" spread="25.3270"/>
                    <measurement group_id="O2" value="-26.535" spread="26.3998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA (Change at Week 14)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="311"/>
                    <count group_id="O2" value="316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.583" spread="26.7955"/>
                    <measurement group_id="O2" value="-25.323" spread="26.8562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA (Change at Week 22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="301"/>
                    <count group_id="O2" value="310"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.558" spread="27.5077"/>
                    <measurement group_id="O2" value="-26.486" spread="26.7141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA (Change at Week 30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.186" spread="28.6488"/>
                    <measurement group_id="O2" value="-28.814" spread="28.5929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGAA (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="325"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.362" spread="16.2520"/>
                    <measurement group_id="O2" value="64.126" spread="16.7220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGAA (Change at Week 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="318"/>
                    <count group_id="O2" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.913" spread="18.5574"/>
                    <measurement group_id="O2" value="-20.143" spread="17.1407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGAA (Change at Week 4)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="315"/>
                    <count group_id="O2" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.724" spread="19.2226"/>
                    <measurement group_id="O2" value="-27.905" spread="17.9803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGAA (Change at Week 6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="312"/>
                    <count group_id="O2" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.319" spread="20.1143"/>
                    <measurement group_id="O2" value="-30.958" spread="18.9303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGAA (Change at Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="310"/>
                    <count group_id="O2" value="318"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.827" spread="19.8162"/>
                    <measurement group_id="O2" value="-33.919" spread="19.7020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGAA (Change at Week 14)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="310"/>
                    <count group_id="O2" value="316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.870" spread="21.4707"/>
                    <measurement group_id="O2" value="-34.175" spread="20.6526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGAA (Change at Week 22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="300"/>
                    <count group_id="O2" value="311"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.542" spread="20.8619"/>
                    <measurement group_id="O2" value="-36.118" spread="20.6564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGAA (Change at Week 30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="293"/>
                    <count group_id="O2" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.842" spread="22.0276"/>
                    <measurement group_id="O2" value="-36.666" spread="22.1598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2</title>
        <description>PAAP: Participants assessed the severity of their arthritis pain by using a 100 mm VAS ranging from 0 (no pain) to 100 (most severe pain), which corresponded to the magnitude of their pain, where higher scores indicated more pain. PGA: Participants were asked the following question, &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; and their response was recorded on a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated worse health condition. PGAA: Participants were assessed how their overall arthritis appears at the time of the visit. The evaluation was based on the participant's disease signs, functional capacity and physical examination, and was independent of the PAAP and PGA assessments. The physician's response was recorded using a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated more disease activity.</description>
        <time_frame>Baseline (Week 30 pre-dose), Week 38, 46 and 54</time_frame>
        <population>The ITT Population was defined as all participants who were randomized to study treatment. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2: PF-06438179/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of PF-06438179 in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O2">
            <title>Period 2: INX/INX</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive INX in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O3">
            <title>Period 2: INX/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2</title>
          <description>PAAP: Participants assessed the severity of their arthritis pain by using a 100 mm VAS ranging from 0 (no pain) to 100 (most severe pain), which corresponded to the magnitude of their pain, where higher scores indicated more pain. PGA: Participants were asked the following question, &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; and their response was recorded on a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated worse health condition. PGAA: Participants were assessed how their overall arthritis appears at the time of the visit. The evaluation was based on the participant's disease signs, functional capacity and physical examination, and was independent of the PAAP and PGA assessments. The physician's response was recorded using a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated more disease activity.</description>
          <population>The ITT Population was defined as all participants who were randomized to study treatment. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PAAP (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="278"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.137" spread="24.2922"/>
                    <measurement group_id="O2" value="33.331" spread="22.2738"/>
                    <measurement group_id="O3" value="32.559" spread="22.2702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAAP (Change at Week 38)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="277"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.014" spread="18.7502"/>
                    <measurement group_id="O2" value="1.440" spread="14.9902"/>
                    <measurement group_id="O3" value="-0.705" spread="18.9147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAAP (Change at Week 46)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="269"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.230" spread="20.0201"/>
                    <measurement group_id="O2" value="1.087" spread="21.5811"/>
                    <measurement group_id="O3" value="2.188" spread="20.7319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAAP (Change at Week 54)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="259"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.416" spread="20.7823"/>
                    <measurement group_id="O2" value="-0.492" spread="20.8000"/>
                    <measurement group_id="O3" value="1.365" spread="24.8362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="278"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.104" spread="24.8444"/>
                    <measurement group_id="O2" value="33.268" spread="22.2621"/>
                    <measurement group_id="O3" value="34.029" spread="22.7172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA (Change at Week 38)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="277"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.628" spread="19.1471"/>
                    <measurement group_id="O2" value="1.582" spread="16.0776"/>
                    <measurement group_id="O3" value="-1.086" spread="17.5787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA (Change at Week 46)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="269"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.171" spread="20.3050"/>
                    <measurement group_id="O2" value="0.558" spread="20.6610"/>
                    <measurement group_id="O3" value="0.535" spread="21.3947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA (Change at Week 54)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="259"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.929" spread="20.9396"/>
                    <measurement group_id="O2" value="-0.538" spread="21.1331"/>
                    <measurement group_id="O3" value="0.776" spread="23.8743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGAA (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="278"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.124" spread="19.0943"/>
                    <measurement group_id="O2" value="27.294" spread="18.8148"/>
                    <measurement group_id="O3" value="26.091" spread="17.9503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGAA (Change at Week 38)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="277"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.254" spread="12.4789"/>
                    <measurement group_id="O2" value="0.588" spread="16.5232"/>
                    <measurement group_id="O3" value="-1.852" spread="15.4699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGAA (Change at Week 46)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="269"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.470" spread="13.9135"/>
                    <measurement group_id="O2" value="0.625" spread="20.0163"/>
                    <measurement group_id="O3" value="-0.700" spread="18.8038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGAA (Change at Week 54)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="258"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.252" spread="17.0422"/>
                    <measurement group_id="O2" value="-3.398" spread="20.0381"/>
                    <measurement group_id="O3" value="-2.969" spread="20.1498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3</title>
        <description>PAAP: Participants assessed the severity of their arthritis pain by using a 100 mm VAS ranging from 0 (no pain) to 100 (most severe pain), which corresponded to the magnitude of their pain, where higher scores indicated more pain. PGA: Participants were asked the following question, &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; and their response was recorded on a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated worse health condition. PGAA: Participants were assessed how their overall arthritis appears at the time of the visit. The evaluation was based on the participant's disease signs, functional capacity and physical examination, and was independent of the PAAP and PGA assessments. The physician's response was recorded using a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated more disease activity.</description>
        <time_frame>Baseline (Week 54 pre-dose), Week 62, 70 and 78</time_frame>
        <population>The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 3: PF-06438179/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of PF-06438179 in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O2">
            <title>Period 3: INX/INX/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O3">
            <title>Period 3: INX/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and PF-06438179 in Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3</title>
          <description>PAAP: Participants assessed the severity of their arthritis pain by using a 100 mm VAS ranging from 0 (no pain) to 100 (most severe pain), which corresponded to the magnitude of their pain, where higher scores indicated more pain. PGA: Participants were asked the following question, &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; and their response was recorded on a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated worse health condition. PGAA: Participants were assessed how their overall arthritis appears at the time of the visit. The evaluation was based on the participant's disease signs, functional capacity and physical examination, and was independent of the PAAP and PGA assessments. The physician's response was recorded using a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated more disease activity.</description>
          <population>The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PAAP (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.395" spread="23.7412"/>
                    <measurement group_id="O2" value="31.659" spread="23.2900"/>
                    <measurement group_id="O3" value="31.225" spread="22.9366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAAP (Change at Week 62)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.025" spread="15.8259"/>
                    <measurement group_id="O2" value="0.276" spread="12.2744"/>
                    <measurement group_id="O3" value="-1.790" spread="16.6740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAAP (Change at Week 70)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="118"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.948" spread="18.1105"/>
                    <measurement group_id="O2" value="-0.297" spread="15.4108"/>
                    <measurement group_id="O3" value="-0.970" spread="16.7170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAAP (Change at Week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="238"/>
                    <count group_id="O2" value="116"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.552" spread="18.8760"/>
                    <measurement group_id="O2" value="-2.900" spread="18.0663"/>
                    <measurement group_id="O3" value="-3.918" spread="20.9632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.841" spread="23.7807"/>
                    <measurement group_id="O2" value="31.130" spread="23.3603"/>
                    <measurement group_id="O3" value="32.710" spread="22.6365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA (Change at Week 62)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.240" spread="16.2724"/>
                    <measurement group_id="O2" value="1.463" spread="13.6899"/>
                    <measurement group_id="O3" value="-2.226" spread="15.3415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA (Change at Week 70)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.764" spread="18.7038"/>
                    <measurement group_id="O2" value="0.101" spread="14.4260"/>
                    <measurement group_id="O3" value="-2.093" spread="16.2677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA (Change at Week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="115"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.880" spread="19.6643"/>
                    <measurement group_id="O2" value="-2.339" spread="17.0453"/>
                    <measurement group_id="O3" value="-3.758" spread="19.5447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGAA (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.305" spread="17.6278"/>
                    <measurement group_id="O2" value="21.780" spread="17.3354"/>
                    <measurement group_id="O3" value="20.705" spread="16.9587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGAA (Change at Week 62)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.381" spread="13.6810"/>
                    <measurement group_id="O2" value="2.659" spread="14.6314"/>
                    <measurement group_id="O3" value="-0.499" spread="12.9483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGAA (Change at Week 70)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.217" spread="14.1581"/>
                    <measurement group_id="O2" value="-1.160" spread="12.7665"/>
                    <measurement group_id="O3" value="-0.810" spread="15.0274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGAA (Change at Week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="116"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.217" spread="15.3894"/>
                    <measurement group_id="O2" value="0.681" spread="15.0989"/>
                    <measurement group_id="O3" value="-0.159" spread="17.2024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1</title>
        <time_frame>Baseline (Day 1), Week 2, 4, 6, 12, 14, 22 and 30</time_frame>
        <population>The ITT Population was defined as all participants who were randomized to study treatment. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 1: PF-06438179</title>
            <description>Participants were scheduled to receive intravenous infusions of PF-06438179 at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Period 1: Infliximab-EU Remicade (INX)</title>
            <description>Participants were scheduled to receive intravenous infusions of INX at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1</title>
          <population>The ITT Population was defined as all participants who were randomized to study treatment. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
          <units>milligram/litres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="325"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.916" spread="24.3118"/>
                    <measurement group_id="O2" value="25.366" spread="28.4866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="318"/>
                    <count group_id="O2" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.183" spread="20.8107"/>
                    <measurement group_id="O2" value="-16.140" spread="24.2442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="312"/>
                    <count group_id="O2" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.555" spread="19.5227"/>
                    <measurement group_id="O2" value="-13.407" spread="33.9136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="313"/>
                    <count group_id="O2" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.078" spread="20.4984"/>
                    <measurement group_id="O2" value="-13.247" spread="27.7801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="311"/>
                    <count group_id="O2" value="317"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.502" spread="23.9435"/>
                    <measurement group_id="O2" value="-12.525" spread="27.8736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="310"/>
                    <count group_id="O2" value="314"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.613" spread="23.2548"/>
                    <measurement group_id="O2" value="-12.392" spread="29.3267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="301"/>
                    <count group_id="O2" value="308"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.195" spread="24.5225"/>
                    <measurement group_id="O2" value="-11.422" spread="31.0610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="292"/>
                    <count group_id="O2" value="297"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.165" spread="25.6612"/>
                    <measurement group_id="O2" value="-12.390" spread="30.0352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 38, 46 and 54: Period 2</title>
        <time_frame>Baseline (Week 30 pre-dose), Week 38, 46 and 54</time_frame>
        <population>The ITT Population was defined as all participants who were randomized to study treatment. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2: PF-06438179/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of PF-06438179 in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O2">
            <title>Period 2: INX/INX</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive INX in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O3">
            <title>Period 2: INX/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 38, 46 and 54: Period 2</title>
          <population>The ITT Population was defined as all participants who were randomized to study treatment. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
          <units>milligrams/litres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="278"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.970" spread="19.1927"/>
                    <measurement group_id="O2" value="14.427" spread="21.1595"/>
                    <measurement group_id="O3" value="10.847" spread="14.8018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 38</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="276"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.496" spread="18.7859"/>
                    <measurement group_id="O2" value="1.805" spread="19.5138"/>
                    <measurement group_id="O3" value="0.093" spread="14.8441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 46</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.210" spread="16.1727"/>
                    <measurement group_id="O2" value="3.996" spread="24.4986"/>
                    <measurement group_id="O3" value="0.798" spread="15.7687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="256"/>
                    <count group_id="O2" value="129"/>
                    <count group_id="O3" value="128"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.639" spread="21.1226"/>
                    <measurement group_id="O2" value="2.988" spread="24.5492"/>
                    <measurement group_id="O3" value="1.264" spread="13.6788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 62, 70 and 78: Period 3</title>
        <time_frame>Baseline (Week 54 pre-dose), Week 62, 70 and 78</time_frame>
        <population>The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 3: PF-06438179/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of PF-06438179 in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O2">
            <title>Period 3: INX/INX/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O3">
            <title>Period 3: INX/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and PF-06438179 in Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 62, 70 and 78: Period 3</title>
          <population>The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3. Here, &quot;Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
          <units>milligrams/litres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.112" spread="21.3781"/>
                    <measurement group_id="O2" value="16.096" spread="24.1595"/>
                    <measurement group_id="O3" value="11.985" spread="13.8159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 62</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.635" spread="19.9660"/>
                    <measurement group_id="O2" value="-3.648" spread="21.6177"/>
                    <measurement group_id="O3" value="-0.541" spread="9.3198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 70</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.320" spread="23.1234"/>
                    <measurement group_id="O2" value="-4.199" spread="22.3368"/>
                    <measurement group_id="O3" value="-0.339" spread="11.7095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="115"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.660" spread="19.6340"/>
                    <measurement group_id="O2" value="-3.565" spread="23.9800"/>
                    <measurement group_id="O3" value="0.811" spread="14.7061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (Nab) Status: Period 1</title>
        <description>ADA positive results was defined as ADA titer level &gt;=1.30 and NAb positive was defined as NAb titer level &gt;=0.70.</description>
        <time_frame>Baseline (Day 1) up to Week 30</time_frame>
        <population>Safety population was defined as all participants who were randomized and received at least 1 dose of study treatment, analyzed by actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 1: PF-06438179</title>
            <description>Participants were scheduled to receive intravenous infusions of PF-06438179 at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Period 1: Infliximab-EU Remicade (INX)</title>
            <description>Participants were scheduled to receive intravenous infusions of INX at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (Nab) Status: Period 1</title>
          <description>ADA positive results was defined as ADA titer level &gt;=1.30 and NAb positive was defined as NAb titer level &gt;=0.70.</description>
          <population>Safety population was defined as all participants who were randomized and received at least 1 dose of study treatment, analyzed by actual treatment received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="323"/>
                    <count group_id="O2" value="326"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NAb</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (Nab) Status: Period 2</title>
        <description>ADA positive results was defined as ADA titer level &gt;=1.30 and NAb positive was defined as NAb titer level &gt;=0.70.</description>
        <time_frame>Baseline (Week 30 pre-dose) up to Week 54</time_frame>
        <population>Safety population was defined as all participants who were randomized and received at least 1 dose of study treatment, analyzed by actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2: PF-06438179/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of PF-06438179 in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O2">
            <title>Period 2: INX/INX</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive INX in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O3">
            <title>Period 2: INX/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (Nab) Status: Period 2</title>
          <description>ADA positive results was defined as ADA titer level &gt;=1.30 and NAb positive was defined as NAb titer level &gt;=0.70.</description>
          <population>Safety population was defined as all participants who were randomized and received at least 1 dose of study treatment, analyzed by actual treatment received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="280"/>
                    <count group_id="O2" value="143"/>
                    <count group_id="O3" value="143"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NAb</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (Nab) Status: Period 3</title>
        <description>ADA positive results was defined as ADA titer level &gt;=1.30 and NAb positive was defined as NAb titer level &gt;=0.70.</description>
        <time_frame>Baseline (Week 54 pre-dose) up to Week 78</time_frame>
        <population>Safety population was defined as all participants who were randomized and received at least 1 dose of study treatment, analyzed by actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 3: PF-06438179/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of PF-06438179 in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O2">
            <title>Period 3: INX/INX/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O3">
            <title>Period 3: INX/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and PF-06438179 in Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (Nab) Status: Period 3</title>
          <description>ADA positive results was defined as ADA titer level &gt;=1.30 and NAb positive was defined as NAb titer level &gt;=0.70.</description>
          <population>Safety population was defined as all participants who were randomized and received at least 1 dose of study treatment, analyzed by actual treatment received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="126"/>
                    <count group_id="O3" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NAb</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentration Versus Time Summary: Period 1</title>
        <time_frame>Pre dose on Day 1, 15, 43, 99, 155 and 211; 2 hours post dose on Day 1 and 99; and 336 hours post dose on Day 29</time_frame>
        <population>Pharmacokinetic population: all treated participants from per protocol (PP) population, who had at least 1 post-dose drug concentration measurement during Period 1. PP population: all participants who were randomized and received the study treatment as planned up to Week 14, with no major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 1: PF-06438179</title>
            <description>Participants were scheduled to receive intravenous infusions of PF-06438179 at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Period 1: Infliximab-EU Remicade (INX)</title>
            <description>Participants were scheduled to receive intravenous infusions INX at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentration Versus Time Summary: Period 1</title>
          <population>Pharmacokinetic population: all treated participants from per protocol (PP) population, who had at least 1 post-dose drug concentration measurement during Period 1. PP population: all participants who were randomized and received the study treatment as planned up to Week 14, with no major protocol deviations.</population>
          <units>nanograms/milliliters</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (0 hours)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="322"/>
                    <count group_id="O2" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1635" spread="11163"/>
                    <measurement group_id="O2" value="656.2" spread="6583.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (2 hours)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65310" spread="24920"/>
                    <measurement group_id="O2" value="62220" spread="22129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (0 hours)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="316"/>
                    <count group_id="O2" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17350" spread="8391.4"/>
                    <measurement group_id="O2" value="16690" spread="8002.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (336 hours)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="308"/>
                    <count group_id="O2" value="314"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23640" spread="12357"/>
                    <measurement group_id="O2" value="21570" spread="10986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (0 hours)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="308"/>
                    <count group_id="O2" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11440" spread="10101"/>
                    <measurement group_id="O2" value="10100" spread="7721.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99 (0 hours)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="302"/>
                    <count group_id="O2" value="310"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3547" spread="9559.2"/>
                    <measurement group_id="O2" value="2559" spread="6360.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99 (2 hours)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="297"/>
                    <count group_id="O2" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76030" spread="39407"/>
                    <measurement group_id="O2" value="73350" spread="41410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155 (0 hours)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="295"/>
                    <count group_id="O2" value="303"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2051" spread="3440.9"/>
                    <measurement group_id="O2" value="1566" spread="2321.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 211 (0 hours)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="281"/>
                    <count group_id="O2" value="290"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1781" spread="2765.2"/>
                    <measurement group_id="O2" value="2112" spread="11703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentration Versus Time Summary: Period 2</title>
        <time_frame>Pre dose on Day 211, 267, 379 and 547</time_frame>
        <population>Pharmacokinetic population: all treated participants from per protocol (PP) population, who had at least 1 post-dose drug concentration measurement during Period 1. PP population: all participants who were randomized and received the study treatment as planned up to Week 14, with no major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2: PF-06438179/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of PF-06438179 in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O2">
            <title>Period 2: INX/INX</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive INX in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
          <group group_id="O3">
            <title>Period 2: INX/PF-06438179</title>
            <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentration Versus Time Summary: Period 2</title>
          <population>Pharmacokinetic population: all treated participants from per protocol (PP) population, who had at least 1 post-dose drug concentration measurement during Period 1. PP population: all participants who were randomized and received the study treatment as planned up to Week 14, with no major protocol deviations.</population>
          <units>nanograms/milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 211 (0 hours)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="278"/>
                    <count group_id="O2" value="143"/>
                    <count group_id="O3" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1801" spread="2773.4"/>
                    <measurement group_id="O2" value="1083" spread="1763.6"/>
                    <measurement group_id="O3" value="1819" spread="2393.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 267 (0 hours)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="272"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1855" spread="2871.7"/>
                    <measurement group_id="O2" value="1208" spread="1926.5"/>
                    <measurement group_id="O3" value="1620" spread="2413.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 379 (0 hours)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="125"/>
                    <count group_id="O3" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2075" spread="4054.6"/>
                    <measurement group_id="O2" value="1823" spread="6110.8"/>
                    <measurement group_id="O3" value="1734" spread="2725.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 547 (0 hours)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="499.6" spread="1373.0"/>
                    <measurement group_id="O2" value="212.7" spread="405.18"/>
                    <measurement group_id="O3" value="3305" spread="8429.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentration Versus Time Summary: Period 3</title>
        <time_frame>Pre dose on Day 379, 435 and 547</time_frame>
        <population>Pharmacokinetic population: all treated participants from per protocol (PP) population, who had at least 1 post-dose drug concentration measurement during Period 1. PP population: all participants who were randomized and received the study treatment as planned up to Week 14, with no major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Period 3: PF-06438179/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of PF-06438179 in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O2">
            <title>Period 3: INX/INX/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
          <group group_id="O3">
            <title>Period 3: INX/PF-06438179/PF-06438179</title>
            <description>Participants received intravenous infusions of INX in Period 1 and PF-06438179 in Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentration Versus Time Summary: Period 3</title>
          <population>Pharmacokinetic population: all treated participants from per protocol (PP) population, who had at least 1 post-dose drug concentration measurement during Period 1. PP population: all participants who were randomized and received the study treatment as planned up to Week 14, with no major protocol deviations.</population>
          <units>nanograms/milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 379 (0 hours)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="250"/>
                    <count group_id="O2" value="125"/>
                    <count group_id="O3" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2078" spread="4044.0"/>
                    <measurement group_id="O2" value="1823" spread="6110.8"/>
                    <measurement group_id="O3" value="1734" spread="2725.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 435 (0 hours)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="118"/>
                    <count group_id="O3" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1913" spread="2838.0"/>
                    <measurement group_id="O2" value="1388" spread="2387.4"/>
                    <measurement group_id="O3" value="1572" spread="2543.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 547</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1707" spread="2512.9"/>
                    <measurement group_id="O2" value="1663" spread="5305.7"/>
                    <measurement group_id="O3" value="1482" spread="2441.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Period 1: Baseline (Day 1) up to Week 30, Period 2: Baseline (Week 30 pre-dose) up to Week 54, Period 3: Baseline (Week 54 pre-dose) up to Week 78</time_frame>
      <desc>Safety population was defined as all participants who are randomized and receive at least 1 dose of study treatment, analyzed by actual treatment received. The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non serious in another participant, or 1 participant may have experienced both a serious and non serious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Period 1: PF-06438179</title>
          <description>Participants were scheduled to receive intravenous infusions of PF-06438179 at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Period 1: Infliximab-EU Remicade (INX)</title>
          <description>Participants were scheduled to receive intravenous infusions of INX at a dose of 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessment. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Period 2: PF-06438179/PF-06438179</title>
          <description>Participants randomized to receive intravenous infusions of PF-06438179 in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
        </group>
        <group group_id="E4">
          <title>Period 2: INX/INX</title>
          <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive INX in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
        </group>
        <group group_id="E5">
          <title>Period 2: INX/PF-06438179</title>
          <description>Participants randomized to receive intravenous infusions of INX in Period 1 were scheduled to receive PF-06438179 in Period 2 at a dose of 3 mg/kg or 5 mg/kg on Weeks 30, 38 and 46. Period 2 ended with the completion of the Week 54 pre-dose assessments.</description>
        </group>
        <group group_id="E6">
          <title>Period 3: PF-06438179/PF-06438179/PF-06438179</title>
          <description>Participants received intravenous infusions of PF-06438179 in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
        </group>
        <group group_id="E7">
          <title>Period 3: INX/INX/PF-06438179</title>
          <description>Participants received intravenous infusions of INX in Period 1 and Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
        </group>
        <group group_id="E8">
          <title>Period 3: INX/PF-06438179/PF-06438179</title>
          <description>Participants received intravenous infusions of INX in Period 1 and PF-06438179 in Period 2. In Period 3 they were scheduled to receive PF-06438179 at a dose of 3 mg/kg or 5 mg/kg on Weeks 54, 62 and 70. Period 3 ended at Week 78.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Blood disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Multi-organ disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Purulent synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Bone abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Ocular lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Genital prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 19.0; 20.0">Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Venous stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02222493
org study id: B5371002
secondary id: REFLECTIONS B537-02
secondary id: 2013-004148-49
nct id: NCT02222493
lead sponsor: 
has dmc: Yes
The study will assess the efficacy and safety of PF-06438179 and infliximab in combination
      with methotrexate in subjects with active rheumatoid arthritis who have had an inadequate
      response to methotrexate.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1
time frame: Week 14
description: ACR20 response: greater than or equal to (>=) 20 percent (%) improvement in tender joint count (TJC); >= 20% improvement in swollen joint count (SJC); and >= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity (PGA); physician global assessment of disease activity; self-assessed disability (health assessment questionnaire-disability index [HAQ-DI]); and C-Reactive Protein (CRP).
measure: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2, 4, 6, 12, 22 and 30 (Pre-dose): Period 1
time frame: Week 2, 4, 6, 12, 22 and 30 (pre-dose)
description: ACR20 response: >=20% improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; HAQ-DI and CRP.
measure: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 38, 46 and 54 (Pre-dose): Period 2
time frame: Week 38, 46 and 54 (pre-dose)
description: ACR20 response: >=20% improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; HAQ-DI and CRP.
measure: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 62, 70 and 78: Period 3
time frame: Week 62, 70 and 78
description: ACR20 response: >=20% improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; HAQ-DI and CRP.
measure: Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1
time frame: Week 2, 4, 6, 12, 14, 22 and 30 (pre-dose)
description: ACR50 response: >=50% improvement in tender joint count, >=50% improvement in swollen joint count improvement and >=50% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP. ACR70 response: >=70% improvement in tender joint count, >=70% improvement in swollen joint count improvement and >=70% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP.
measure: Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2
time frame: Week 38, 46 and 54 (pre-dose)
description: ACR50 response: >=50% improvement in tender joint count, >=50% improvement in swollen joint count improvement and >=50% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP. ACR70 response: >=70% improvement in tender joint count, >=70% improvement in swollen joint count improvement and >=70% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP.
measure: Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3
time frame: Week 62, 70 and 78
description: ACR50 response: >=50% improvement in tender joint count, >=50% improvement in swollen joint count improvement and >=50% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP. ACR70 response: >=70% improvement in tender joint count, >=70% improvement in swollen joint count improvement and >=70% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP.
measure: Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1
time frame: Baseline (Day 1), Week 2, 4, 6, 12, 14, 22 and 30
description: DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on visual analogue scale [VAS] from 0 to 100 mm; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) less than (<)2.6=remission, <3.2=low disease activity, >=3.2-5.1=moderate disease activity and greater than (>) 5.1=high disease activity. HAQ-DI assess degree of difficulty a participant experienced (past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.
measure: Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2
time frame: Baseline (Week 30 pre-dose), Week 38, 46 and 54
description: DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on VAS from 0 to 100 millimeter [mm]; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) <2.6=remission, <3.2=low disease activity, >=3.2-5.1=moderate disease activity and >5.1=high disease activity. HAQ-DI assess degree of difficulty a participant experienced (past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.
measure: Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3
time frame: Baseline (Week 54 pre-dose), Week 62, 70 and 78
description: DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on VAS from 0 to 100 mm; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) <2.6=remission, <3.2=low disease activity, >=3.2-5.1=moderate disease activity and >5.1=high disease activity. HAQ-DI assess degree of difficulty a participant experienced (past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.
measure: Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1
time frame: Week 2, 4, 6, 12, 14, 22 and Week 30 (pre-dose)
description: ACR/EULAR remission was considered if the scores on tender joint count, swollen joint count, hs-CRP (mg/dL), and patient's global assessment of arthritis (PGA) all were less than or equal to (=<) 1 or the score on the simplified disease activity index (SDAI) was =<3.3. SDAI was calculated as the sum of number of tender and swollen joint count (using 28 joints), PGA, physician global assessment, and CRP (mg/dL). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. Physician global assessment was recorded on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicated more disease activity. DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, CRP (mg/dL) and PGA using a 10 mm-VAS from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. DAS28 <3.2: low disease activity, DAS28 <2.6: remission.
measure: Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2
time frame: Week 38, 46 and 54 (pre-dose)
description: ACR/EULAR remission was considered if the scores on tender joint count, swollen joint count, hs-CRP (mg/dL), and PGA all were =<1 or the score on the SDAI was =<3.3. SDAI was calculated as the sum of number of tender and swollen joint count (using 28 joints), PGA, physician global assessment, and CRP (mg/dL). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. Physician global assessment was recorded on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicated more disease activity. DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, CRP (mg/dL) and PGA using a 10 mm-VAS from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. DAS28 <3.2: low disease activity, DAS28 <2.6: remission.
measure: Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3
time frame: Week 62, 70 and 78
description: ACR/EULAR remission was considered if the scores on tender joint count, swollen joint count, hs-CRP (mg/dL), and PGA all were =<1 or the score on the SDAI was =<3.3. SDAI was calculated as the sum of number of tender and swollen joint count (using 28 joints), PGA, physician global assessment, and CRP (mg/dL). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. Physician global assessment was recorded on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicated more disease activity. DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, CRP (mg/dL) and PGA using a 10 mm-VAS from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. DAS28 <3.2: low disease activity, DAS28 <2.6: remission.
measure: Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1
time frame: Week 2, 4, 6, 12, 14, 22 and Week 30 (pre-dose)
description: EULAR response was based on DAS28 EULAR response criteria which was defined as good response = DAS28 change of >1.2 with DAS28 =<3.2; moderate response = DAS28 change of >0.6 to =<1.2 with DAS28 >3.2-5.1 and no-response = DAS28 change of =<0.6 with DAS28 >5.1.
measure: Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2
time frame: Week 38, 46 and Week 54 (pre-dose)
description: EULAR response was based on DAS28 EULAR response criteria which was defined as good response = DAS28 change of >1.2 with DAS28 =<3.2; moderate response = DAS28 change of >0.6 to =<1.2 with DAS28 >3.2-5.1 and no-response = DAS28 change of =<0.6 with DAS28 >5.1.
measure: Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3
time frame: Week 62, 70 and Week 78
description: EULAR response was based on DAS28 EULAR response criteria which was defined as good response = DAS28 change of >1.2 with DAS28 =<3.2; moderate response = DAS28 change of >0.6 to =<1.2 with DAS28 >3.2-5.1 and no-response = DAS28 change of =<0.6 with DAS28 >5.1.
measure: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 1
time frame: Baseline (Day 1) up to Week 30
description: An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Week 30 that were absent before treatment or that worsened relative to pre-treatment state. Treatment-related TEAE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non-serious adverse events.
measure: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 2
time frame: Baseline (Week 30 pre-dose) up to Week 54
description: An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Week 54 that were absent before treatment or that worsened relative to pre-treatment state. Treatment-related TEAE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non-serious adverse events.
measure: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 3
time frame: Baseline (Week 54 pre-dose) up to Week 78
description: An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Week 78 that were absent before treatment or that worsened relative to pre-treatment state. Treatment-related TEAE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non-serious adverse events.
measure: Number of Participants With Treatment Emergent Adverse Events (TEAEs) of Grade 3 or Higher Severity: Period 1
time frame: Baseline (Day 1) up to Week 30
description: AEs were graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) Version 4.03 as Grades 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life threatening AEs and Grade 5= death related to AE. AEs of Grade 3 and higher severity are reported in this outcome measure.
measure: Number of Participants With Treatment Emergent Adverse Events (TEAEs) of Grade 3 or Higher Severity: Period 2
time frame: Baseline (Week 30 pre-dose) up to Week 54
description: AEs were graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) Version 4.03 as Grades 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life threatening AEs and Grade 5= death related to AE. AEs of Grade 3 and higher severity are reported in this outcome measure.
measure: Number of Participants With Treatment Emergent Adverse Events (TEAEs) of Grade 3 or Higher Severity: Period 3
time frame: Baseline (Week 54 pre-dose) up to Week 78
description: AEs were graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) Version 4.03 as Grades 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life threatening AEs and Grade 5= death related to AE. AEs of Grade 3 and higher severity are reported in this outcome measure.
measure: Number of Participants With Laboratory Abnormalities: Period 1
time frame: Baseline (Day 1) up to Week 30
description: Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count, lymphocytes, neutrophils: <0.8*lower limit of normal (LLN); platelets: >1.75*upper limit of normal (ULN); white blood cell count: <0.6*LLN; basophils, eosinophils, monocytes: >1.2*ULN. liver function: bilirubin: >1.5*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: >3.0*ULN; protein, albumin: <0.8*LLN></0>1.2*ULN; renal function:blood urea nitrogen,creatinine: >1.3*ULN; uric acid: >1.2*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: <0.9*LLN,>1.1*ULN; urinalysis: pH<4.5, >8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: <0.6*LLN,>1.5*ULN). Participants with any laboratory abnormality in Period 1 were reported in this outcome measure.
measure: Number of Participants With Laboratory Abnormalities: Period 2
time frame: Baseline (Week 30 pre-dose) up to Week 54
description: Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count, lymphocytes, neutrophils: <0.8*lower limit of normal (LLN); platelets: >1.75*upper limit of normal (ULN); white blood cell count: <0.6*LLN; basophils, eosinophils, monocytes: >1.2*ULN. liver function: bilirubin: >1.5*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: >3.0*ULN; protein, albumin: <0.8*LLN></0>1.2*ULN; renal function:blood urea nitrogen,creatinine: >1.3*ULN; uric acid: >1.2*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: <0.9*LLN,>1.1*ULN; urinalysis: pH<4.5, >8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: <0.6*LLN,>1.5*ULN). Participants with any laboratory abnormality in Period 2 were reported in this outcome measure.
measure: Number of Participants With Laboratory Abnormalities: Period 3
time frame: Baseline (Week 54 pre-dose) up to Week 78
description: Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count, lymphocytes, neutrophils: <0.8*lower limit of normal (LLN); platelets: >1.75*upper limit of normal (ULN); white blood cell count: <0.6*LLN; basophils, eosinophils, monocytes: >1.2*ULN. liver function: bilirubin: >1.5*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: >3.0*ULN; protein, albumin: <0.8*LLN></0>1.2*ULN; renal function:blood urea nitrogen,creatinine: >1.3*ULN; uric acid: >1.2*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: <0.9*LLN,>1.1*ULN; urinalysis: pH<4.5, >8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: <0.6*LLN,>1.5*ULN). Participants with any laboratory abnormality in Period 3 were reported in this outcome measure.
measure: Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1
time frame: Baseline (Day 1), Week 2, 4, 6, 12, 14, 22 and Week 30
description: Tender joint count was an assessment of 68 joints (upper body, upper extremity, and lower extremity). Each joint's response to pressure/motion was assessed as: Present or Absent. Swollen joint count was an assessment of 66 joints (upper body, upper extremity, and lower extremity). Each joint was assessed for swelling as: Present or Absent.
measure: Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2
time frame: Baseline (Week 30 pre-dose), Week 38, 46 and Week 54
description: Tender joint count was an assessment of 68 joints (upper body, upper extremity, and lower extremity). Each joint's response to pressure/motion was assessed as: Present or Absent. Swollen joint count was an assessment of 66 joints (upper body, upper extremity, and lower extremity). Each joint was assessed for swelling as: Present or Absent.
measure: Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3
time frame: Baseline (Week 54 pre-dose), Week 62, 70 and 78
description: Tender joint count was an assessment of 68 joints (upper body, upper extremity, and lower extremity). Each joint's response to pressure/motion was assessed as: Present or Absent. Swollen joint count was an assessment of 66 joints (upper body, upper extremity, and lower extremity). Each joint was assessed for swelling as: Present or Absent.
measure: Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1
time frame: Baseline (Day 1), Week 2, 4, 6, 12, 14, 22 and 30
description: PAAP: Participants assessed the severity of their arthritis pain by using a 100 mm VAS ranging from 0 (no pain) to 100 (most severe pain), which corresponded to the magnitude of their pain, where higher scores indicated more pain. PGA: Participants were asked the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" and their response was recorded on a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated worse health condition. PGAA: Participants were assessed how their overall arthritis appears at the time of the visit. The evaluation was based on the participant's disease signs, functional capacity and physical examination, and was independent of the PAAP and PGA assessments. The physician's response was recorded using a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated more disease activity.
measure: Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2
time frame: Baseline (Week 30 pre-dose), Week 38, 46 and 54
description: PAAP: Participants assessed the severity of their arthritis pain by using a 100 mm VAS ranging from 0 (no pain) to 100 (most severe pain), which corresponded to the magnitude of their pain, where higher scores indicated more pain. PGA: Participants were asked the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" and their response was recorded on a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated worse health condition. PGAA: Participants were assessed how their overall arthritis appears at the time of the visit. The evaluation was based on the participant's disease signs, functional capacity and physical examination, and was independent of the PAAP and PGA assessments. The physician's response was recorded using a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated more disease activity.
measure: Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3
time frame: Baseline (Week 54 pre-dose), Week 62, 70 and 78
description: PAAP: Participants assessed the severity of their arthritis pain by using a 100 mm VAS ranging from 0 (no pain) to 100 (most severe pain), which corresponded to the magnitude of their pain, where higher scores indicated more pain. PGA: Participants were asked the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" and their response was recorded on a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated worse health condition. PGAA: Participants were assessed how their overall arthritis appears at the time of the visit. The evaluation was based on the participant's disease signs, functional capacity and physical examination, and was independent of the PAAP and PGA assessments. The physician's response was recorded using a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated more disease activity.
measure: Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1
time frame: Baseline (Day 1), Week 2, 4, 6, 12, 14, 22 and 30
measure: Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 38, 46 and 54: Period 2
time frame: Baseline (Week 30 pre-dose), Week 38, 46 and 54
measure: Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 62, 70 and 78: Period 3
time frame: Baseline (Week 54 pre-dose), Week 62, 70 and 78
measure: Number of Participants With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (Nab) Status: Period 1
time frame: Baseline (Day 1) up to Week 30
description: ADA positive results was defined as ADA titer level >=1.30 and NAb positive was defined as NAb titer level >=0.70.
measure: Number of Participants With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (Nab) Status: Period 2
time frame: Baseline (Week 30 pre-dose) up to Week 54
description: ADA positive results was defined as ADA titer level >=1.30 and NAb positive was defined as NAb titer level >=0.70.
measure: Number of Participants With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (Nab) Status: Period 3
time frame: Baseline (Week 54 pre-dose) up to Week 78
description: ADA positive results was defined as ADA titer level >=1.30 and NAb positive was defined as NAb titer level >=0.70.
measure: Serum Concentration Versus Time Summary: Period 1
time frame: Pre dose on Day 1, 15, 43, 99, 155 and 211; 2 hours post dose on Day 1 and 99; and 336 hours post dose on Day 29
measure: Serum Concentration Versus Time Summary: Period 2
time frame: Pre dose on Day 211, 267, 379 and 547
measure: Serum Concentration Versus Time Summary: Period 3
time frame: Pre dose on Day 379, 435 and 547
arm group label: PF-06438179
arm group type: Experimental
arm group label: Infliximab
arm group type: Active Comparator
intervention type: Biological
intervention name: PF-06438179
description: PF-06438179 will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
arm group label: PF-06438179
other name: Infliximab-Pfizer
intervention type: Biological
intervention name: Infliximab
description: Infliximab will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
arm group label: Infliximab
other name: Infliximab-EU, Remicade
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Pfizer CT.gov Call Center
role: Study Director
affiliation: Pfizer
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Australia
country: Bosnia and Herzegovina
country: Brazil
country: Bulgaria
country: Canada
country: Czechia
country: Georgia
country: Germany
country: Guatemala
country: Hungary
country: Israel
country: Japan
country: Jordan
country: Korea, Republic of
country: Lithuania
country: Mexico
country: Morocco
country: Peru
country: Philippines
country: Poland
country: Romania
country: Russian Federation
country: Serbia
country: South Africa
country: Tunisia
country: Ukraine
country: United Kingdom
country: United States
country: Colombia
country: Czech Republic
country: France
url: https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5371002&StudyName=A%20Study%20of%20PF-06438179%20%28Infliximab-Pfizer%29%20and%20Infliximab%20in%20Combination%20with%20Methotrexate%20in%20Subjects%20with%20Active%20Rheumatoid%20Arthritis%20
description: To obtain contact information for a study center near you, click here.
responsible party type: Sponsor
mesh term: Arthritis
mesh term: Arthritis, Rheumatoid
mesh term: Infliximab
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 